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The HIV epidemic is an ongoing global health challenge. Prevention strategies are one 
means to combat HIV. Part of prevention incudes behavior modifications, circumcision, vaccine 
product development and oral and topical pre-exposure prophylaxis (PrEP). Topical PrEP 
products, also referred to as topical microbicides, are designed for vaginal or rectal application 
for the purpose of prevention of HIV-1 sexual transmission. Products being designed are coitally 
or pericoitally dependent or provide sustained release of the active agent for long term 
protection. The potency of antiretrovirals (ARVs) in HIV therapy promoted the exploration of 
their use as topical microbicides. Dapivirine (DPV) and Tenofovir (TFV) are replication 
inhibitors which have been explored as topical microbicides most widely in clinical trials. A 1% 
TFV vaginal gel applied in a coitally dependent fashion was shown to reduce HIV acquisition by 
39%. However, other trials have not been able to show similar successful results with use of the 
same TFV gel. Therefore, to improve efficacy, combinations of ARVs are being pursued as 
topical microbicides. The development and characterization of a polymeric vaginal film 
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containing DPV and TFV is presented in this dissertation. Drug – drug compatibility and a solid 
state solubility for polymer selection process are described. Physical and chemical 
characterization of the film demonstrated acceptable film properties. Efficacy testing in vitro 
showed the film to be effective at preventing HIV infection. Finally, stability testing proved the 
film to be stable at different environmental conditions for 6 months. Moreover, as ARVs drug 
tissue level is important for their bioactivity, the impact of the co-delivery of TFV and DPV on 
their tissue accumulation and distribution was assessed in an excised human ecto-cervical model. 
Results showed that the film was able to release both agents from the film for subsequent 
delivery into the target tissue. Interestingly, the data showed that the combination film product 
resulted in achieving higher DPV tissue amounts in the stroma whereas no impact on TFV tissue 
accumulation was observed. Collectively, these results provide evidence of the ability of 
polymeric films to accommodate ARVs combinations and illustrate the impact of co-delivery on 
drug tissue accumulation and distribution. 
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1. INTRODUCTION 
 
1.1 HIV “The Epidemic” 
Despite progress in combating the human immunodeficiency virus (HIV) epidemic in the 
past decade, HIV remains a major health challenge. By the end of 2011, 34 million people were 
living with HIV globally. There is, however, a disproportionate distribution of people living with 
HIV between countries. The hardest hit area remains Sub-Saharan Africa with one in twenty 
adults living with HIV. AIDS related death accounted for 1.7 million deaths globally in 2011. 
Nevertheless as a sign of the progress made, the number of new infections in 2011 was 20% 
lower than in 2001 [1].  
The vast majority of new HIV infections are through sexual transmission. Although 
behavior change and advocating condom use can have a positive impact on new HIV infection 
rates, these strategies have not been sufficient to significantly decrease HIV infection rate. 
Behavior change is a complex and lengthy process that is faced with different cultural and social 
norms across the world. Condom use is also associated with steep challenges that arise from 
social, cultural and economic factors which differ for each country. Data showed that male 
circumcision is effective at reducing the risk of HIV infection [2, 3]. In 2007 the World Health 
Organization (WHO) recommended voluntary medical male circumcision as a way to reduce 
HIV infection in males.  
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Women represented 49% of people living with HIV worldwide in 2011. Yet they are 
affected disproportionately in the hardest hit areas such as Sub-Saharan Africa where women 
accounted for 58% of people living with HIV in 2011 (Figure 1.1). This feminization of the 
epidemic prompted focus on prevention strategies for women. A woman’s ability to protect 
herself from HIV infection is hindered by socio-economic norms. Furthermore, due to 
anatomical factors, women are more susceptible to HIV sexual transmission [1].  
 
 
 
Figure 1.1 Women’s share of people living with HIV by region at the end of 2011 
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1.2 HIV-1 Female Sexual Transmission 
1.2.1 The Female Genital Mucosa 
Anatomical sites in the female lower genital tract include: vagina, ectocervix and 
endocervix. The ability for HIV-1 penetration and infection has been established at each of these 
sites [4]. The vaginal and ecto-cervical mucosa is comprised of a multilayered non-keratinized 
stratified squamous epithelium covering lamina propria and vascularized tissue. The multilayer 
epithelium is further subdivided into: basal, parabasal, intermediate, and superficial [5]. As the 
cells migrate from the basal layer upwards to the superficial layer they become flatter. In 
contrast, the endocervix is covered with a single layer of mucus secreting columnar epithelium 
resting on a vascularized lamina propria [6].  
The surface of the epithelium in the female genital mucosa is covered with a hydrophilic 
mucus layer called the glycocalyx. This layer provides a protective barrier against foreign 
pathogen invasion. It consists mainly of glycoproteins (mucins) and water. Mucus is a 
semipermeable barrier that allows the exchange of some materials such as nutrients, water, and 
hormones while being impermeable to most bacteria and many pathogens. Mucus is 
continuously secreted and shed or degraded. The robust barrier mechanism of mucus includes 
entrapment and immobilization of pathogens before they reach the epithelial surface [7]. To 
establish infection, cell free and cell-associated HIV-1 must penetrate the mucus barrier that 
coats and adheres to vaginal epithelia during sexual intercourse. Mucus limits the number of 
virions that reach the epithelium. Through this mechanism mucus can reduce the probability of 
infection [8].  
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1.2.2 HIV-1 Entry to the Female Genital Mucosa 
HIV-1 sexual transmission can occur by vaginal or rectal routes. The probability of HIV-
1 transmission per exposure act via the rectal route (1 in 200 – 1 in 300) is higher than the 
vaginal route (1 in 200 – 1 in 2000) [4]. Vaginal intercourse carries a relatively low risk of HIV-
1 transmission per coital act. The female genital tract is equipped with natural defense 
mechanisms to infection such as the epithelial barrier, acidic pH, and hydrogen peroxide secreted 
by innate microflora. The risk of infection increases when any of these natural defenses is 
compromised. Despite these natural defenses HIV-1 can penetrate and establish an infection in 
the female genital tissue. The main events in the HIV-1 transmission process are: viral entry to 
the mucosa, infection of target cells, and dissemination to regional lymph nodes to initiate 
systemic infection [9]. HIV-1 transmission and target cells are discussed below however it is 
important to mention that for the establishment of productive infection a local expansion of the 
initially infected cells occurs by an influx of CD4+ T-cells leading to the formation of the so-
called founder cell population [10]. This population is thought to produce a sufficient number of 
new virions to support viral dissemination to draining lymph nodes. 
The process of transmission starts when semen containing cell free or cell associated 
virus is deposited in the vagina. HIV-1 infection can be established by both free and cell-
associated virus therefore both forms can successfully penetrate the mucosa [11, 12].  Some of 
the deposited cell associated or free virus is trapped in cervico-vaginal mucus (CVM). Using 3D 
visualization and volume modeling Maher et al. showed that mucus was able to provide some 
protection to the epithelium by trapping HIV-1 virions which were shown to be suspended in 
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mucus above the columnar endocervical epithelium [13]. The mechanisms by which mucus 
prevents viruses such as HIV-1 from infecting mucosal surfaces are not fully understood. 
However, it is generally believed that by steric obstruction mucus can exclude particles that are 
larger than the effective size of its pores. Depending on the methods used, mucus pore size 
estimates range from approximately 100 nm to 500–800 nm, and even 1,000–10,000 nm or 
larger using various conventional electron microscopy (EM) procedures [14]. Using non-
mucoadhesive nanoparticles and multiple particles tracking (MPT), the mucus pore size in fresh 
undiluted human mucus was found to be in the range of approximately 50–1800 nm [14]. 
However, a study with cervico-vaginal mucus obtained from healthy women with dominant 
lactobacilli flora demonstrated efficient trapping of HIV-1 in the mucus [15]. In this study the 
trapping properties of mucus were attributed to the presence of lactic acid secreted from 
lactobacilli the predominant innate mircoflora. Regardless of the mechanism, HIV-1 trapping in 
the mucus may increase viral mucus residence time which can have a positive or negative 
outcome. Immobilization of the virus can allow for it to be attacked by innate defenses, 
conversely it may provide more time for the virus to interact with the mucosa which can foster 
transmission.  
Several target cells of HIV-1 have been identified in the sub-epithelium. Those include 
CD4+ T-cells, macrophages and dendritic cells (DCs). For this reason the initial entry events 
leading to HIV-1 reaching and infecting sub-epithelial target cells are of great interest. 
Nonetheless, the exact mechanism(s) by which HIV-1 enters the female genital mucosa are not 
fully understood. It is proposed that HIV-1 mucosal tissue entry may occur via several pathways 
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including: physical breach or abrasions in the epithelium, direct infection of epithelial cells, 
transcellular transport across epithelial cells or transcytosis, sequestration or endocytosis in 
epithelial cells, and uptake by or infection of intraepithelial immune cells [4, 11, 16, 17]. It is 
highly likely that HIV-1 entry occurs through a combination of pathways with a varying degree 
of contribution of each pathway. 
The integrity of the epithelium lining the genital mucosa is critical to the natural defense 
against pathogen invasion. Any breach in the epithelial barrier opens routes for HIV-1 to invade 
the mucosa. The epithelium could be disrupted due to physical abrasions caused by sexual 
trauma, inflammation induced by sexually transmitted infections (STIs) such as bacterial 
vaginosis (BV) or other ulcer inducing infections [18-20]. Interestingly, it was found that direct 
exposure of genital epithelial monolayer to HIV-1 decreases the trans-epithelial resistance (TER) 
across the epithelium. This reduction was due to a significant decrease in tight junction protein 
expression thus leading to increased permeability indicating an impairment in barrier function 
[21]. Increased permeability of the epithelial barrier could allow transmission of normally 
excluded pathogens [22]. Any gaps or loss of barrier in the epithelium provide the virus with 
access to intra- and sub- epithelial cellular targets (such as T-cells and Langerhans cells) in 
addition to gaining access to basal and parabasal epithelial cells which are thought to be more 
susceptible to HIV-1 binding, endocytosis, or transcytosis [4, 11]. Additionally the presence of 
trauma, infection or inflammation leads to the secretion of pro-inflammatory cytokines and 
chemokines which in turn help in recruiting HIV-1 target immune cells (such as T-cells) [16]. 
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Another proposed process of HIV-1 entry is transcytosis. In this process, the HIV-1 virus 
crosses from the apical to the basal side of the epithelial cells. Cell surface glycosphingolipids, 
sulphated lactosylceramide expressed by vaginal epithelial cells and galactosylceramide 
expressed by ecto-cervical epithelial cells were implicated in fostering trancytosis [23]. 
Nevertheless, it was reported, using cultured primary genital cells, that the efficiency of 
transcytosis seem to be low and could only account for a small portion of HIV-1 entry to the 
genital mucosa [24]. Direct infection of epithelial cells is another suggested mechanism of HIV-1 
entry and penetration of female genital mucosa. This pathway however is controversial as data 
has not been shown to be consistent with regard to direct infection of epithelial cells by HIV-1 
[25, 26]. Another mechanism of HIV-1 entry involving epithelial cells is endocytosis [4, 11]. 
Also several reports have shown that HIV-1 could bind to epithelial cells from the lower female 
genital tract via a variety of cell surface molecules [4, 17]. What role this binding plays in HIV-1 
entry into and infection of female genital mucosa is unclear. 
Once HIV-1 is in the epithelium it comes in contact with intra-epithelial immune cells 
mainly CD4+ T-cells and Langerhans cells (LCs). CD4+ T-cells are the primary target of HIV-1 
virus infection. The infection of these cells is fusion mediated and involves the CD4 receptor and 
chemokine co-receptors CCR5 or CXCR4. The presence of these cells in the epithelium suggests 
that they could play a role in HIV-1 entry to the genital mucosa [9]. Additionally, intra-epithelial 
LCs may be involved in HIV-1 entry to the genital mucosa. Yet the role of LCs in viral entry is 
still debated. It was demonstrated that vaginal intra-epithelial LCs commonly expresses CD4 and 
CCR5 receptors [27]. This finding suggests that intra-epithelial LCs could be infected with HIV-
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1 and become a transmitter of infection to underlying cellular targets. On the other hand studies 
have shown that vaginal intra-epithelial LCs can sequester HIV-1 virus through multiple 
receptors [28]. One receptor that is potentially involved in HIV-1 endocytosis into vaginal LCs is 
the C-type lectin langerin. This receptor binds to HIV-1 surface glycoprotein gp120 in a 
mannose dependent fashion. Langerin was identified to be efficient in binding to HIV-1 leading 
to virus sequestration into epidermal LCs [29].  The infection or sequestration of HIV-1 in intra-
epithelial immune cells can allow for its transfer to sub-epithelial target cells where infection is 
propagated.   
 
1.2.3 HIV-1 Target Cells  
 After HIV-1 penetrates the epithelium of the female genital mucosa, it encounters 
mononuclear target cells in the sub-epithelium. Those targets include CD4+ T-cells, dendritic 
cells and macrophages. 
The HIV-1 infection process starts with viral entry through a fusion dependent manner 
through different cell surface receptors. Once viral RNA is in the host cell, the reverse 
transcriptase enzyme converts the single - stranded viral RNA to double-stranded proviral DNA. 
The newly formed DNA integrates into the host cell DNA via viral integrase enzyme. When the 
host cell receives an activation signal, the proviral DNA utilizes host RNA polymerase to create 
copies of the HIV-1 genomic material, as well as shorter strands of mRNA which are used as a 
blueprint to make long chains of HIV-1 proteins. Viral enzyme protease cuts the long chains of 
the viral proteins into smaller individual proteins. As the HIV proteins come together with copies 
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of the viral RNA, a new virus particle is assembled. The newly assembled virus buds out from 
the host cell moving to infect a new cell [30]. 
It has been established that the primary target of HIV-1 is lymphocytes (CD4+ T-cells) 
[11, 18]. The stroma of the human female genital tract is rich with CD4+ T-cells [31]. Analysis 
of the type of CD4+ T-cells in human cervico-vaginal tissue ex vivo revealed that they are mostly 
effector memory cells with broad expression of CCR5 [32]. HIV-1 can directly infect CD4+ T-
cells using viral surface epitops (gp120, gp41) and cell surface receptors CD4 and CCR5 [33]. 
CD4+ T-cells can also be infected through cell mediated transmission. Efficient HIV-1 infection 
of CD4+ T-cells mediated by DCs, macrophages and other infected CD4+ T-cells has been 
demonstrated [28]. This cell mediated transmission occurs through a virological synapse which 
is a complex that forms at the interface between HIV-1 infected and uninfected cells. Its 
assembly is driven by gp120 interaction with CD4 and CCR5 or CXCR4 coreceptors and 
depends upon stable cell-cell junctions maintained by adhesion molecules [34, 35]. 
 Another cellular target of HIV-1 infection is dendritic cells. DCs consist of an array of 
subsets that differ in origin, maturation state and location. There are a considerable number of 
studies implicating DCs in HIV-1 mucosal transmission [4, 28]. The major role of DCs in HIV-1 
mucosal transmission is enhancement of infection [28]. DCs express the C-type lectin DC-SIGN 
(dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin) receptor. HIV-1 
attachment to DC-SIGN leads to virus endocytosis and preservation without productively 
infecting DCs. HIV-1 bearing DCs can subsequently transfer endocytosed HIV-1 to CD4+ T-
cells prior to viral degradation in the endosome [28]. Additionally, productive infection of DCs 
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has been demonstrated in vitro. However, this matter remains debatable and warrants further 
investigation [4]. Studies showed that lower female genital tract DCs are the first to capture HIV-
1 within the first 2 hours of viral exposure [9]. 
Macrophages residing in the cervico-vaginal stroma are also considered a target of HIV-
1. Although their infection and role are still ambiguous, infection of macrophages was illustrated 
in human cervical explant culture [36]. Macrophages are also thought to be mediator in 
transmitting HIV-1 to CD4+ T-cells [28, 37]. 
 
1.3 Prevention of HIV-1 Sexual Transmission by Topical Microbicides 
As the HIV epidemic continues to spread with no cure or vaccine available, prevention 
has become a primary focus in combating the epidemic. Specific to this work, significant effort 
has been directed into prevention of sexual transmission of HIV. Behavioral change and 
promoting safe sexual practices including condom use are effective but have proven to be 
insufficient as they face cultural norms and socioeconomic factors. Male circumcision has also 
been recommended as an effective way to reduce risk of HIV infection. Additionally, there is a 
feminization of HIV epidemic especially in the hardest hit areas such as sub-Saharan Africa 
where women account for the majority of people living with HIV. Thus there is an urgent need 
for a female controlled method for prevention of HIV sexual transmission.  
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1.3.1 Definition and Classification 
Topical microbicides or topical pre-exposure prophylaxis (PrEP) are products that can be 
applied vaginally or rectally for the purpose of prevention of sexually transmitted infections 
including sexual transmission of HIV-1 [38]. It has been estimated that a 60% effective 
microbicide can prevent millions of new infections each year [39]. 
An ideal topical microbicide product must be safe and effective [40]. The product must 
not harm the natural defenses that exist in the genital tract. It also must not induce any type of 
inflammation or immune response that could lead to an influx of immune cells which are cellular 
targets of HIV-1. In addition, a topical microbicide product must be acceptable and affordable 
[41]. Since topical microbicides are designed to prevent sexual transmission of HIV-1, their 
acceptability by both partners is essential to ensure user compliance. Finally, as the HIV 
epidemic severity is highest in developing countries, it is important that a low cost topical 
microbicide is made available for distribution in these parts of the world. Hence feasibility of 
purchase in developing countries with low economic and purchasing powers is needed.  
 Topical vaginal microbicides are classified by their primary mechanism of action [12, 20, 
40, 42-45]. Vaginal defense enhancers work by strengthening or supporting the natural defense 
mechanisms in the vagina. Such products help maintain the vaginal pH in an acidic range 
(examples are BufferGel and Acidform) or facilitate colonization of vaginal flora with 
lactobacilli. Surfactants or detergents are another class of agents tested as microbicides. 
Surfactants were the first to be evaluated for topical HIV prevention in human clinical studies. 
Their mechanism of action involves nonspecifically disrupting the viral envelope by solublizing 
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membrane proteins. One example of a surfactant which was evaluated as a topical microbicide is 
nonoxynol-9 (N-9), a vaginal contraceptive agent. N-9 failed in clinical testing due to safety 
concerns that led to an increase in HIV infections [46]. A third category of topical microbicides 
are polyanionic polymers such as cellulose sulfate and the natural polymer carrageenen. These 
agents exert their anti-HIV activity by nonspecifically binding to viral membrane and blocking 
fusion events. Other classes of microbicide candidates have specific mechanism of action against 
HIV-1. Entry or fusion inhibitors (such as Cyanovirin-N, Griffithsin, Maraviroc) target viral 
membrane epitopes (gp120, gp41) or cell receptors (CD4, CCR5, and CXCR4) to prevent the 
sequence of viral binding, fusion, and entry that leads to cell infection. Another promising class 
of specific anti-HIV agents is replication inhibitors. Current replication inhibitors (such as 
Tenofovir and Dapivirine) work by inhibiting HIV-1 reverse transcriptase and preventing viral 
replication. There are two sub-classes of replication inhibitors: nucleotide/nucleoside and non-
nucleoside reverse transcriptase inhibitors [47]. Replication inhibitors are further discussed in 
section 1.3.2. Finally, most recently integrase and protease inhibitors are being evaluated as 
candidates for use in microbicide products [48, 49]. Integrase inhibitors such as Raltegravir and 
Elvitegravir are in early testing and development as candidate topical microbicides. They bind to 
the viral integrase enzyme active site and block viral DNA strand transfer to the host genomic 
material [33]. On the other hand the protease inhibitors saquinavir and darunavir are among a 
group of drugs from this class being tested as candidate topical micrbicides. Protease inhibitors 
block viral protease enzyme activity that is required for post-translational processing of precursor 
viral proteins into functional proteins for the budded virion to be infectious. 
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As the drug candidates used in topical microbicides evolved in terms of their specificity 
to HIV-1, another classification system is used that categorizes microbicides in three classes 
based on their specificity to HIV-1. These classes are non-specific, moderately specific and HIV-
specific. Nonspecific microbicides include detergents and buffering agents; moderately specific 
microbicides include anionic polymers, dendrimers, and small polyanionic molecules. Both 
frequently target more than one pathogen. The HIV-specific microbicides include entry, 
integrase, protease, and reverse transcriptase inhibitors [44, 50]. 
 
1.3.2 The Replication Inhibitors Dapivirine & Tenofovir 
 Replication inhibitors (RIs), or reverse transcriptase inhibitors, were the first HIV 
specific antiretrovirals (ARVs) to enter topical microbicides clinical trials. Their basic 
mechanism of action is blocking the replication of viral RNA to proviral DNA. There are two 
classes of RIs: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) and non-
nucleoside reverse transcriptase inhibitors (NNRTIs).  
Tenofovir (TFV or PMPA), (9-[(R)-2-(phosphonomethoxy) propyl] adenine 
monohydrate), is an NtRTIs (Figure 1.2). It blocks reverse transcription by competing with 
natural nucleotide incorporation in the forming proviral DNA chain. That results in the 
termination of DNA synthesis because TFV lacks the 3-hydroxyl group necessary to form the 
ester bond with the next nucleotide [48, 49]. However, for TFV to be active it must undergo two 
phosphorylation steps. Of note, NRTIs require three phosphorylation steps for activation [47-49]. 
One key feature of TFV that may render it a suitable candidate as topical microbicide is that its 
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active form has a long cellular half-life which may support prolonged anti-HIV activity even 
with coital independent dosing regimens [47, 51]. It should be noted that TFV is used in HIV 
therapy as an ester prodrug called tenofovir disoproxil fumarate (TDF) [52]. Two oral products 
manufactured by Gilead Sciences Inc. contain either TDF only (VIREAD®) or in combination 
with the NRTI emtricitabine (FTC) (TRUVADA®) are used in HIV therapy. 
 
 
 
Figure 1.2 Chemical structure of tenofovir (TFV) 
 
 
 
 
As a topical microbicide, a 1% TFV vaginal gel was tested in vitro and ex vivo and 
showed effectiveness in preventing HIV-1 infection [53]. The gel was evaluated in macaque 
animal models and showed complete protection of animals from SHIV (simian human 
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immunodeficiency virus) infection [54]. TFV gel was shown to provide protection for an 
extended period of time. Dobard et al demonstrated that 1% TFV gel applied vaginally provided 
protection to 4/6 macaques against SHIV infection when virus exposure was performed 3 days 
after gel application [51].  
In clinical trials, a two week course of 1% TFV vaginal gel used twice daily was safe and 
well tolerated in sexually abstinent and sexually active HIV-negative and positive women [55]. 
In another clinical study, TFV gel applied once daily was shown to increase the anti-HIV activity 
of cervico-vaginal lavage (CVL) in a dose dependent manner. This activity was shown to persist 
in the presence of semen [56]. However, in clinical efficacy trials, TFV evaluated as topical 
microbicide or oral PrEP has not shown consistent results [57]. In a phase IIb study 
(CAPRISA004), 1% TFV vaginal gel provided 39% reduction in HIV-1 acquisition when used in 
a coital dependent manner [58]. This was the first proof of concept that an ARV based topical 
microbicide could be used for HIV prevention. However, in another clinical trial (VOICE) the 
same gel was not effective in preventing HIV acquisition when used once daily in a coitally 
independent application [59]. TFV has also been evaluated in clinical trials as oral PrEP. In a 
clinical trial (called iPrEx) the daily oral use of TDF/FTC combination was able to reduce HIV 
acquisition by 44% in men who have sex with men (MSM) and transgender women [60]. The 
same oral TDF/FTC combination was tested in high risk HIV negative women for efficacy. The 
study was stopped due to futility as the number of infections was equal between the placebo and 
the active groups [57]. The Partners PrEP study showed that TDF/FTC daily oral use reduced 
HIV acquisition by 73% compared to placebo in HIV serodiscordant couples [57]. Currently, 
16 
 
two an ongoing phase III clinical trials (FACTS001 and CAPRISA008) are evaluating the 1% 
TFV vaginal gel in heterosexual women for efficacy with coitally dependent use to confirm 
results of CAPRISA004. In addition to its anti-HIV activity, TFV was shown to block herpes 
simplex virus (HSV) infection as well [61].  
Dapivirine (DPV, TMC120) (4[4-[(2,4,6-trimethylphenyl)amino-2-
pyrimidinyl]amino]benzonitrile), is an NNRTI (Figure 1.3). Developed and evaluated in clinical 
trials as therapeutic agent, DPV exhibited low bioavailability when administered orally therefore 
it is only being pursued as topical microbicide product. NNRTIs are noncompetitive inhibitors 
that bind with high affinity to an allosteric binding pocket on the reverse transcriptase enzyme 
thereby blocking enzyme activity and halting HIV-1 replication [62]. Specifically, NNRTIs bind 
to a single site, which is ~10 angstroms away from the polymerase active site, on the p66 subunit 
of the viral reverse transcriptase enzyme p66/p51 heterodimer [63]. This binding induces 
conformational changes in the enzyme and causes parts of it to be rigid. The two events lead to 
an alteration of the substrate-enzyme binding mode and/or affect the translocation of the double 
strand leading to non-competitive inhibition of the enzyme [62]. Resistance to NNRTIs is 
associated with mutations of the amino acids that make up the binding pocket on the p66 subunit. 
Because of their mechanism of action, NNRTIs are generally lipophilic compounds and unlike 
NRTIs/NtRTIs, no phophorylation is required for NNRTIs to be active [47].  
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Figure 1.3 Chemical structure of dapivirine (DPV) 
 
DPV has been shown in vitro and ex vivo to possess anti-HIV activity when used in 
nanomolar levels  against various HIV-1 isolates and a wide range of NNRTI-resistant HIV-1 
isolates [64]. DPV was able to prevent HIV-1 infection by cell free or cell associated virus in co-
cultures of monocyte-derived DCs (MO-DCs) and CD4+ T-cells after 24 hours treatment [65]. 
Pre-treatment of cell free HIV-1 with DPV blocked subsequent infection of MO-DCs and CD4+ 
T-cells co-cultures [66]. The findings in this study support the notion that NNRTIs can permeate 
cell free HIV-1 and may be able to inactivate the virus before its penetrates the epithelium or 
reaches its target cells [47]. Evaluation of DPV in a dual chamber model of cervical epithelial 
cells confirmed its ability to block HIV-1 infection of MO-DCs and CD4+ T-cells by cell 
associated virus [67]. In a non-polarized ecto-cervical tissue explant model, DPV was shown to 
inhibit HIV-1 infection in concentrations as low as 0.1 nM with complete inhibition of infection 
at 10 nM as determined by the detection of proviral DNA [64]. A vaginal gel containing DPV 
was shown to be successful in preventing HIV-1 vaginal transmission by cell associated HIV in a 
humanized severe combined immunodeficient (hu-SCID) mouse model [68]. A gel formulation 
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of C
14
-DPV applied once daily in rabbits or macaques resulted in high concentrations of DPV in 
vaginal and cervical tissues for >24 hours with low plasma concentration [69]. DPV was also 
formulated in a vaginal ring to be used as a sustained release topical microbicide [70].  
In clinical trials, there have been eight completed clinical trials evaluating safety, 
pharmacokinetics (PK) and acceptability of the DPV vaginal gel, and six completed clinical trials 
evaluating safety and PK of the DPV vaginal ring (Appendix I). In healthy HIV negative women 
DPV vaginal gel applied twice daily for 42 days was shown to be safe and well tolerated [71]. 
Another phase I study evaluated vaginal gels, containing a range of DPV concentrations (25, 50 
and 150 μM), applied twice daily for 7 days in HIV negative and positive women. Results of the 
study showed that all concentrations tested were well tolerated with low systemic absorption 
[72]. Two phase I studies evaluating the PK of DPV vaginal gel showed good DPV distribution 
in the female lower genital tract with low systemic absorption associated with gel use over the 
study period [73, 74]. Intravaginal rings containing DPV were evaluated in two Phase 1 studies 
for safety and PK over a seven day application period. DPV ring formulations showed safety and 
effective delivery of DPV to the lower genital tract. Systemic absorption of DPV was found to be 
low with levels <50 pg/ml [75]. In another Phase 1 study which compared matrix and reservoir 
DPV vaginal rings, 28 day use was well tolerated and did not induce any serious or severe 
adverse events [76]. Currently, two phase III trials are ongoing evaluating the long term safety 
and efficacy of the DPV vaginal ring applied for 4 weeks. 
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1.3.3 Combination Microbicides 
In clinical trials, several topical microbicide products failed to significantly reduce HIV 
acquisition. The only success of a topical microbicide in efficacy testing is the TFV vaginal gel 
as tested in the CAPRISA004 trial. However, the efficacy of the product was low (39% reduction 
in infection rates). In order to improve the efficacy of topical microbicides, several strategies 
such as use of combinations have been adopted. It is expected that a topical microbicide product 
containing a combination of anti-HIV drug candidates will have an improved efficacy [38]. The 
benefit of combination microbicides is increased barrier to infection particularly if the drug 
candidates block HIV infection at different stages of the viral cycle with distinct mechanism of 
action. Additionally, a reduction in the dose required for each drug may be possible if they act 
additively or synergistically. This could theoretically reduce the potential for toxicity and 
resistance [38, 48, 49, 77].  
To date many antiretroviral (ARV) drug combinations have been evaluated [78]. A 
combination of cellulose acetate 1, 2-benzenedicarboxylate (CAP), a polymer that 
nonspecifically blocks HIV-1 entry, and UC781, an NNRTI, was tested in vitro and resulted in 
significant synergistic and complementary effects against HIV-1 infection [79]. This resulted in 
meaningful dose reductions for each compound. Maraviroc (MVC), a CCR5 antagonist, was 
shown in vitro to have additive effect when combined with replication inhibitors including TFV 
[80]. Similarly, an additive effect was demonstrated in vitro in the combination of MIV-150 
(NNRTI) and carrageenan. The 50% effective concentration (EC50) showed the combination to 
be 10 times more potent than carrageenan only [81]. A gel containing a combination of 2.5% 
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TFV and 1% IQP-0528 was tested in vitro and ex vivo in ecto-cervical and colorectal tissues 
[82]. Results showed that in vitro both drugs exhibited a 50% effective dose in nanomolar levels 
and the gel was able to protect the tissues from HIV-1 infection. In animal models, Parikh et al. 
showed that a vaginal gel containing 1% TFV and 5% FTC applied twice-weekly fully protected 
macaques from a total of 20 exposures to simian-human immunodeficiency virus [54]. In rhesus 
macaques, a MIV-150/zinc acetate combination gel was shown to fully protect the animals as 
opposed to partial protection by either active agent individually [83]. Other combinations have 
been developed and/or evaluated as potential combination microbicide products [84-88]. 
Recently, a study by Schader et al. showed that the combination of TFV and DPV exerts additive 
effect against wild type HIV-1 and synergistic effect against NNRTI resistant HIV-1 tested in 
vitro in TZM-bl cell line [89]. Furthermore, it was shown that different HIV-1 strains and 
subtypes grown in tissue culture containing suboptimal concentrations of DPV and TFV had 
fewer NNRTI resistance mutations as compared to when the tissue culture contained suboptimal 
concentrations of DPV only [90]. 
 
1.3.4 Status of Topical Microbicides in Clinical Trials 
The first topical microbicide product to be evaluated in clinical trials contained the 
surfactant Nonoxynol-9. The product failed due to safety concerns as the product was proven 
toxic to the genital mucosa [46]. Other non-specific topical microbicide products (such as 
Carraguard, cellulose sulfate, Buffergel and PRO2000) failed in clinical trials due lack of 
efficacy [91-96]. However, as research and development of topical microbicides moved towards 
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the use of specific anti-HIV agents represented by ARVs, the first sign of success emerged. The 
phase IIb clinical trial (CAPRISA 004) showed that a 1% TFV vaginal gel administered 12 hours 
before and after vaginal sexual intercourse reduced HIV-1 acquisition by an overall 39% and by 
54% in women with high gel adherence [58]. However, as described previously in section 1.3.2 
data regarding TFV from other efficacy trials have been conflicting. The other advanced ARV 
being evaluated in clinical trials is DPV. Multiple clinical trials have proven the safety of DPV 
vaginal gel and ring as discussed in section 1.3.2.  
Currently, there are multiple phase III clinical trials ongoing evaluating the efficacy of 
the TFV gel and the DPV vaginal ring (Appendix II). Additionally, several phase I safety trials 
are ongoing evaluating safety of other products including combination microbicide. 
 
1.4 Delivery of Topical Vaginal Microbicides 
  A successful safe and effective topical microbicide product fundamentally hinges on 
delivery system design. Efficacy, safety, and acceptability will be influenced by the dosage form 
choice and design attributes of the delivery system. Formulation of topical microbicide products 
faces numerous challenges. 
 
1.4.1 Challenges and Considerations 
 Several factors determine dosage form choice and design. The physical and chemical 
properties of the active pharmaceutical agent (API), drug candidate mechanism of action and the 
biological environment each contribute to formulation of the dosage form [38, 97, 98].  
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Although each product faces its own specific challenges related to its design and 
function, drug delivery to the vagina is generally met with common obstacles. The vagina is 
naturally equipped with defense mechanisms to protect against foreign pathogens or exogenous 
substances. These mechanisms represent a barrier to drug delivery to the vagina. The vaginal 
fluid contains water, mucus, enzymes, proteins, and cellular debris. All these components have 
the ability to interact with the API or dosage form causing loss in activity, destabilization of the 
API, and impact on dosage form retention and distribution [5]. As explained in section 1.2.2, the 
presence of mucus in the vagina works as a natural barrier to HIV-1 transmission. Water 
insoluble compounds must not only be able to dissolve in vaginal fluids but also cross the 
aqueous mucus barrier. The delivery system chosen for such APIs must be able to enhance or 
overcome this solubility issue. Use of cyclodextrins and nanoparticles has been demonstrated as 
a remedy for the dissolution of water insoluble compounds in vaginal fluids [99, 100]. Thickness 
of the epithelium of the mucosal tissue plays a role in the permeability and tissue accumulation 
of APIs. This is specifically an issue for APIs that work inside the tissue or on cellular levels. 
Cyclic changes, age, use of hormonal contraception and other factors all impact the thickness of 
the epithelium [101]. Other biological factors in the vagina such as acidic pH, presence of 
lactobacilli and enzymatic activity must be considered for the delivery of topical microbicides.  
From a drug development stand point, topical microbicide development requires 
consideration of several factors. Understanding of the mechanism of action of the API is 
essential to identity the appropriate delivery systems which would achieve the right delivery and 
targeting for optimal API function. For topical microbicides, delivery systems for ARVs must be 
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able to deliver these compounds to the site of action in the tissue because ARVs work on cellular 
level. On the other hand pre-formulation studies are important to conduct in order to determine 
parameters such as API stability, water solubility and anti-HIV activity. These parameters are 
necessary to understand in order to optimize the delivery system attributes so that product safety 
and efficacy are maximized. For example if stability in aqueous environment is an issue for an 
API, use of excipients to stabilize the API or use of a solid dosage form may be required. 
Additionally, retention of API anti-HIV activity after formulation must be assured. Therefore, 
delivery systems that require heat or high shear in their fabrication may be challenging to use 
especially with biopharmaceuticals. One of the considerations for topical microbicide products is 
the retention and distribution of the dosage form in the vaginal lumen. This is important to assess 
because it has implications for an array of outcomes ranging from local tissue PK to consumer 
acceptability. Hydrogels, depending on their formulation, show the ability to spread and cover 
most of the cervico-vaginal surface [102-104]. That could be beneficial for distributing the API 
across the cervico-vaginal tissue in order to provide protection against HIV-1 infection. However 
the ability of hydrogel to spread in the vaginal lumen is often associated with product leakage 
which could hinder acceptability and lead to loss of API. Conversely, while vaginal rings do not 
have leakage issues they rely on the ability of the API to distribute throughout the cervico-
vaginal tissue which may be limited due to the inherent properties of the API [105] and the 
limited volume of fluids available in the vagina. Another important factor to consider in topical 
microbicide delivery is safety. The delivery system should not induce any immune response or 
cause harm to the natural defenses and components of the vaginal ecosystem including natural 
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microflora [106]. An induction in immune response leads to recruitment of HIV-1 target cells. 
The delivery system should not cause disruption of the epithelium which would allow for easier 
access for HIV-1 to reach its target cells. 
Additional factors are to be considered for combination microbicide delivery. The degree 
of complexity increases when designing a delivery system for combination microbicides. For 
instance the compatibility of the two API together must be evaluated. Co-delivery of APIs may 
cause a change in local tissue concentrations by impacting transport and clearance of both APIs. 
The delivery system should account for any impact of co-delivery on local tissue drug levels in 
order to maximize efficacy particularly as changes in drug tissue levels could affect product 
efficacy especially with the use of ARVs.  
Finally, consumer acceptability of any microbicide product is essential to the success of 
the product. Therefore, formulation of the same in API in different dosage form may be needed 
in order to increase consumer acceptability and adherence to use of the product [107].  
 
1.4.2 Vaginal Polymeric Films for Topical Microbicides Delivery 
Several dosage forms have been clinically investigated for use as drug delivery systems 
for topical microbicide [5, 108, 109]. Hydrogels have been the most widely studied for vaginal 
delivery of topical microbicides. However, this dosage form is largely associated with messiness, 
product leakage, and requires an applicator. In addition, the relatively large gel dosing volume 
can potentially cause dilution or alteration of vaginal fluids leading to loss of natural antiviral 
activity [105]. Water soluble polymeric films offer an alternative delivery strategy for topical 
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microbicides. Films are solid dosage forms that dissolve once placed on a moist mucosal surface. 
This dosage form offers fast and accurate dose administration and can be administered without 
an applicator. Other advantages of vaginal films include the potential for discreet use and 
decreased product volume [5, 105, 109]. The low product volume of vaginal films reduces the 
potential for product leakage with use. From a product development stand point films are 
convenient reproducible dosage forms that can be used to stabilize drugs that are susceptible to 
degradation in aqueous environments. Previous results from acceptability studies with vaginal 
films showed that women preferred films over other vaginal dosage forms [110-113]. A recent 
acceptability study of vaginal films, soft-gel capsules, and tablets as potential topical microbicide 
delivery systems showed that films were highly acceptable [114]. The film was chosen more 
often than a soft-gel capsule (SGC) or tablet as the preferred dosage form for use (39% and 37% 
vs. 25%, respectively). More women preferred to use films (61%) rather than the SGC (53%) or 
tablet (49%). 
A typical film formulation is comprised of the active pharmaceutical ingredient (API), 
film forming polymers, plasticizers, and other excipients such as disintegrants [115]. For vaginal 
application, polymers used are usually water soluble such as cellulose derivatives, polyvinyl 
alcohol, pullulan, gums (xanthan, locust bean, and guar) and chitosan. The type of polymer used 
and its molecular weight can significantly impact the properties of the film such as mechanical 
strength, disintegration rate and dissolution. Additionally, plasticizers are used in film 
formulation to provide flexibility to allow the film to endure mechanical stress such as that 
encountered during use. Glycerin, sorbitol, propylene glycol, and citrate derivatives are examples 
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of plasticizers used in film formulations. The amount and type of plasticizer used in the 
formulation can impact the mechanical properties of the film. Other excipients used in film 
formulation may vary depending on its use. For instance, disintegration agents such as 
polyethylene glycol (PEG) are used to provide fast disintegration and quick drug release [116]. 
An example of a marketed vaginal film is the Vaginal Contraceptive Film (VCF). 
Polymeric films have been studied for vaginal administration of antifungal and antibacterial drug 
candidates [117-119]. Topical microbicide products formulated as polymeric films for vaginal 
application have been developed and evaluated [120-125]. A water dispersible microbicidal 
cellulose acetate phthalate film was also developed as a topical microbicide [121]. The film was 
shown to rapidly inactivate HIV-1 and HSV. A vaginal film containing 300 mg Polystyrene 
sulfonate (PSS), a noncytotoxic antimicrobial contraceptive agent, was developed. The PSS films 
showed activity against HIV-1 comparable to PSS drug substance [122]. A bioadhesive vaginal 
film containing zidovudine (AZT), an NRTI, has been developed [126]. Film bioadhesion was 
shown to proportionally correlate with the percentage of hydroxypropyl methyl cellulose 
(HPMC) in the film formulation. Proteins and peptides with anti-HIV activity were also 
formulated into vaginal films. One example is RC-101, a synthetic microbicide analog of 
retrocyclin, which has been shown in vitro to have activity against HIV-1. A film formulation 
containing 100 µg RC-101 per film unit was developed [124]. The film was shown to be active 
against HIV-1 both in in vitro and ex vivo studies and maintained in vitro bioactivity for at least 6 
months. 
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1.4.3 Pharmacokinetics: The Importance of Mucosal Tissue Drug Levels to Efficacy 
 Optimizing drug delivery systems for microbicides requires attention to a host of 
parameters as described previously. Pharmacokinetic parameters in terms of distribution and 
clearance are what ultimately dictate local drug tissue concentration in the mucosa. The delivery 
system of an anti-HIV agent needs to achieve the goal of delivering the API to the intended site 
of action in a concentration and duration sufficient to outweigh and outlast the virus so 
prevention of HIV-1 transmission is blocked [107]. Since the replication inhibitors DPV and 
TFV are both active within the tissue/cells, local PK analysis is essential to better understand the 
delivery efficiency of these drugs from the dosage form to the site of action [127].  
Optimizations (including the excipients used) made to the delivery system can change the 
local mucosal drug concentration. Grammen et al. developed an in vitro system to assess the 
impact of formulation excipients on microbicide drug permeation [128]. The study showed that 
TFV had a much higher flux across HEC-1A cell line than DPV when delivered from an aqueous 
based gel. That is likely due to the aqueous solubility of TFV. However, DPV flux could be 
enhanced 30 fold by use of excipients such as polyetheylen glycol (PEG) and cyclodextrins in 
the gel. A change in flux or permeation will impact local tissue concentrations. Clinical data also 
exist illustrating how the delivery system impacts local tissue PK parameters. A phase I clinical 
study evaluated the PK of two DPV vaginal rings (reservoir and matrix) [76]. Results showed 
that both rings were able to successfully deliver DPV to the lower genital tract with 
concentrations 4 logs greater than the reported EC50. However, the maximum concentrations and 
drug exposure were significantly higher with matrix ring use as compared to reservoir ring use.  
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 Both DPV and TFV require delivery into the female lower genital tract tissues giving 
their mechanism of action. It is vital from a drug delivery stand point to understand the impact of 
the delivery system and its formulation on local mucosal tissue drug concentration. This will 
help to assess the functionality of the delivery system to effectively deliver the active agents to 
target and conduct the proper modifications to maximize efficacy of such required delivery. The 
relationship of cellular or tissue concentration to product efficacy was exemplified in 
pharmacokinetic studies with TFV vaginal gel. Hendrix et al. illustrated that there is a positive 
correlation between TFV intracellular concentration and the likelihood for infection with higher 
TFV concentrations resulting in lower infection rates [127]. More recently, analysis of results 
from CAPRISA004 showed that a relationship between HIV-1 incidence rate and TFV 
concentration in aspirated cervico-vaginal fluid (CVL) [129]. In the low-exposure group 
([TFV]VF<1000 ng/mL) HIV incidence rate did not differ from the placebo group whereas the 
rate was significantly lower in high-exposure group ([TFV]VF>1000 ng/mL). Although the 
relationship between tissue and CVL drug concentrations is yet to be made, the positive 
correlation between TFV levels in CVL and efficacy provides an example of how drug levels in 
vivo correlates with overall efficacy.  
 
1.5 Hypothesis and Specific Aims 
Reverse transcriptase inhibitors have gained a great deal of attention recently. They are 
currently considered to be the most promising ant-HIV agents being studied in the clinic. RTIs 
prevent HIV-1 infection by blocking replication of viral RNA to DNA in the target cells. HIV-1 
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has several cellular targets (such as CD4+ T-cells, dendritic cells, and macrophages) in the 
cervico-vaginal tissue. Mostly, these target cells exist in the sub-epithelial tissue. Therefore a 
drug delivery system of RTIs must be able to deliver them to the cervico-vaginal tissue 
efficiently. Dapivirine (DPV) and Tenofovir (TFV) are the most advanced of the RTIs candidates 
currently being developed as topical microbicides. They differ in aqueous solubility with DPV 
being hydrophobic and TFV being hydrophilic. From a drug delivery stand point; once the drug 
is released from its dosage form it becomes available for permeation into the target tissue. The 
process of permeation can be affected by several factors including but not limited to dosage form 
design and drug chemical properties. As a result of permeability kinetics, drug tissue 
concentrations and distribution are determined. This is of great importance to topical 
microbicides containing DPV and/or TFV due to the need for both drugs to be present in the 
tissue site of action in levels sufficient to prevent HIV-1 infection. Polymeric vaginal films offer 
a promising delivery system for topical microbicide drug candidates including RTIs. Polymeric 
films provide portability, do not require an applicator, and have no leakage or messiness. All of 
these benefits can increase user acceptability and compliance. In addition, as a solid dosage form 
polymeric films decreased the dilution effect and more efficiently releases drug payload resulting 
in higher drug concentration at the tissue surface. This can theoretically drive the permeation of 
the drug into the tissue. That is why polymeric films are potentially advantageous to RTIs 
delivery. However, as combination microbicides are being considered for clinical evaluation, it is 
important to assess how co-delivery can influence the tissue permeation and accumulation of 
each drug candidate. 
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We hypothesize that dapivirine and tenofovir can be co-delivered using a water soluble 
polymeric vaginal film. We further hypothesize that co-delivery of dapivirine and tenofovir will 
change their tissue accumulation and distribution in the target mucosal tissue due to 
subsequent changes in drug concentration gradients.  
 
This hypothesis will be addressed through the following specific aims: 
Specific aim 1: Formulation of a water soluble vaginal film containing the hydrophobic reverse 
transcriptase inhibitor dapivirine. 
Specific aim 2: Development and evaluation of a water soluble vaginal film containing a 
combination of dapivirine and tenofovir.  
Specific aim 3: Assessment of impact of co-delivery on dapivirine and tenofovir tissue 
accumulation and distribution in human ecto-cervical tissue model ex vivo.  
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2. FORMULATION OF WATER SOLUBLE VAGINAL FILM CONTAINING 
HYDROPHOBIC DAPIVIRINE 
 
2.1 Introduction 
 As discussed in chapter 1, Dapivirine (DPV) is a potent replication inhibitor that is being 
developed as a topical vaginal microbicide product. It is a tight binding non-nucleoside reverse 
transcriptase inhibitor (NNRTI). The first example of protection using in vitro models with 
NNRTIs was with UC781, a potent anti-HIV drug candidate with hydrophobic nature [100, 130-
132]. As a topical microbicide product, DPV has been formulated and evaluated in vaginal gel 
and intravaginal ring (IVR) dosage forms [68-70, 133-135]. Malcolm et al. showed that a core 
type silicone elastomer vaginal ring containing DPV exhibits zero-order release for 71 days with 
about 140 μg DPV released daily [135]. DPV has also been incorporated in various surface 
engineered poly epsilon-caprolactone (PCL) based nanoparticles. Negatively charged 
nanoparticles were stable up to one year at 5 - 40°C [136]. In clinical trials, DPV vaginal gel 
showed good safety profile and low systemic absorption of DPV [71-74].  Similarly, DPV 
intravaginal rings were evaluated in two Phase 1 studies for safety and PK over a seven day 
application period and showed safety and effective delivery of DPV to the lower genital tract 
with low systemic absorption [75, 76].  
For a topical microbicide to succeed it has to be highly acceptable for use by consumers. 
Therefore user acceptability and compliance must be considered during the development of 
topical microbicides. It is likely that several dosage forms with different attributes will be needed 
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to provide women with more choices which will likely result in improved adherence. Vaginal 
polymeric films for drug delivery are widely studied for delivery of various drugs [137]. The 
advancement in polymer science has allowed for the development of films for a range of 
pharmaceuticals. The merits and acceptability of polymeric films as a dosage form have been 
discussed in chapter 1. 
To address the dissertation hypothesis regarding polymeric films ability to deliver a 
combination of TFV and DPV it is first necessary to establish the capability of a water soluble 
polymeric film to accommodate the hydrophobic drug candidate DPV. Therefore the aim of the 
studies described in this chapter was to develop and characterize a film containing the NNRTI 
DPV for vaginal use to prevent HIV-1 sexual transmission. Comparative studies were carried out 
with drug substance and film formulation to demonstrate that the formulation process did not 
result in significant loss of antiviral activity. In vitro drug release experiments were conducted to 
ensure rapid release of DPV from the film. Drug release is important in that it is required for 
drug permeation upon insertion in vivo. 
 
2.2 Methods 
Dapivirine (DPV) was provided by the International Partnership for Microbicides (IPM). 
DPV is a white micronized powder with molecular weight of 329.4 and pKa of 5.8. It is water 
insoluble (LogP = 5.27 at pH 9) and has a 2.5 mg/mL solubility in propylene glycol. UC781 is 
also a water insoluble NNRTI.  Given that the potent anti-HIV activity of UC781 has been well 
established [132, 138] it was used as a control in in vitro bioactivity studies. 
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2.2.1 Dapivirine Film Formulation 
The film formulation was composed of PVA, HPMC 4000, PEG 8000, propylene glycol, 
and glycerin. Solvent casting methods were used for film manufacture. Briefly, an aqueous film 
solution containing the excipients and DPV (in a dispersed state) was prepared. The solution was 
cast onto a polyester substrate attached to the hot surface of an automatic film applicator 
(Elcometer® 4340) using either a spreading blade with reservoir. After casting, film solution was 
allowed to dry for 20 minutes before it was removed from the substrate. Once film sheets were 
obtained they were cut using a die press into 1” x 2” individual unit doses.  
 
2.2.2 Dapivirine-Excipient Compatibility 
Weighed amounts of DPV were placed in glass vials and mixed with 320 µL propylene 
glycol. Polymer solution (1.68 ml) composed of polyvinyl alcohol (PVA), hydroxypropyl methyl 
cellulose (HPMC) 4000, and polyethylene glycol (PEG) 8000 was added to each vial and 
vortexed. The vials were sealed under nitrogen and protected from light using aluminum foil. 
The vials were placed in conditions of 30°C / 65% relative humidity (RH), 40°C / 75% RH or 
50°C. Drug content was monitored for 14 days at all conditions to assess DPV stability. DPV 
drug content was determined using an ultra-high performance liquid chromatography (UHPLC) 
method. The method utilizes a Waters Acquity BEH C18 1.7µ 2.1x50mm. The mobile phase 
used was (A) 0.08% TFA in water (B) 0.05% TFA in Acetonitrile (ACN). A gradient method 
was used where % of mobile phase (B) changes from 10 – 80 – 10 over 15 minutes run time. 
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2.2.3 Physical and Chemical Characterization 
DPV film weight, thickness and appearance was recorded. Tensile strength as a measure 
of films strength was assessed using a texture analyzer (TA-XT.Plus) connected to a data 
acquisition and analysis software. Tensile strength was calculated using the following equation: 
Tensile strength = Force (N) / Cross sectional area of the film (cm
2
). Residual water content of 
the films was measured using Karl-Fisher apparatus (Metrohm, 758 KFD Titrino). Film 
disintegration testing was conducted by submerging a film in 3 ml water and mixing by rotation 
using an orbital shaker. Disintegration was monitored visually as the time for complete film 
structural loss. For determination of DPV drug content, films were dissolved in a 50% ACN 
solution and heated for 5 minutes at 50˚C. An aliquot was taken from the solution and analyzed 
using the previously described UHPLC method. Dissolution of DPV films was evaluated using a 
class IV USP apparatus (SOTAX CP7) using a 60 mL reservoir and a flow rate of 16 mL/min. 
The dissolution media used was distilled water containing 1% cremophor.  DPV solubility in the 
dissolution media is 40 μg/mL. Film dissolution was monitored under sink conditions for 60 
minutes and DPV was detected by UV spectrometer at 310 nm. 
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2.2.4 Stability Assessment 
DPV films were held for 24 months at 30°C / 65% RH and for 6 months at 40°C / 75% 
RH. Testing of the films was conducted at predetermined time points. At each time points 
weight, thickness, appearance, tensile strength, water content, and drug content were tested.  In 
addition, disintegration, dissolution, Lactobacillus compatibility and in vitro anti-HIV activity 
(TZM-bl cell based model) were tested at specific time points throughout the stability protocol.  
 
2.2.5 Compatibility with Lactobacillus 
The standard microbicide safety test was used as previously described [139, 140] to 
assess Lactobacillus compatibility with DPV vaginal film. Briefly, bacterial suspensions were 
prepared in ACES buffer and the films were then dissolved and mixed in the suspensions. The 
suspensions were then incubated for 30 min at 37°C.  Samples were taken at zero time and again 
after 30 min. Viability was determined by standard plate count. A sample is considered 
compatible if the reduction in viability was < log10. 
 
2.2.6 Dapivirine Tissue Permeability 
Human excised cervical tissue was obtained from University of Pittsburgh Health 
Sciences Tissue Bank under IRB Protocol PRO09110431. Tissue samples were from healthy 
volunteers undergoing routine hysterectomy for non-cervical issues. A section of each tissue was 
retained for histological evaluation. Excess stromal tissue was removed and the epithelial layer 
isolated using a Thomas-Stadie Riggs tissue slicer by a longitudinal slice through the entire 
36 
 
tissue. Tissue thickness was measured by placing the tissue between two pre-measured slides.  
Tissue permeability studies were performed in a Franz cell system. Isolated epithelial sections of 
the tissue were placed between the donor and receptor compartments of the Franz cell with the 
epithelial side of the tissue oriented toward the donor compartment. The tissue-loaded Franz cells 
are maintained in an environment at 37°C throughout the experiment. The receptor was filled 
with 10% PEG 300 in Krebs buffer (pH=4.0). DPV drug substance solubilized in the receptor 
medium (100 μg/mL) or DPV film (sufficient weight of film to obtain 100 μg/mL) solubilized in 
receptor medium (400 μL) was added to the donor chamber. At predetermined time points, 200 
μL was removed from the receptor chamber and replaced with the same volume of fresh 
medium. The collected samples were analyzed for drug content using previously described 
UHPLC methods.  
 
2.2.7 Dapivirine Film In Vitro Anti-HIV Activity 
2.2.7.1 HIV-RT and Cell-Based HIV-1 Replication Assay 
Weighed pieces of DPV films were dissolved in either DMEM (for cell-based assays) or 
1X RT-buffer [for in vitro reverse transcriptase (RT) assays] at 1:10 w/v. Multiple dilutions of 
the starting solutions were then prepared and used. For the RT assay, the ability of each film 
dilution to inhibit the RNA-dependent DNA polymerase activity of HIV-1 RT was determined 
using poly(rA)-oligo(dT) and [3H-TTP] as previously described [100]. Cell-based single HIV-1 
replication cycle assays for direct antiviral activity of the film formulations used P4R5 indicators 
cells as described above.  
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2.2.7.2 TZM-bl Assay 
Anti-HIV activity testing using TZM-bl assay was performed as previously described 
[141]. DPV films or placebo films were dissolved in 2 mL of saline. Ten-fold serial dilutions up 
to 1:107 of the original 2 ml sample of the DPV film were made. The placebo film was handled 
in a similar manner. As a control, the drug substance was used. DPV was dissolved in DMSO 
and serial dilutions beginning at 1000 nM were made using the TZM-bl medium (DMEM with 
10% BSA supplemented with antibiotics). The respective dilutions were added in triplicate to 
plated TZM-bl cells. HIV-1BaL was added next and the assay was cultured for 48 hours. 
Infection was detected by adding BrightGlo (Promega) a chemiluminescent developer of 
luciferase to each well. Control wells comprising cells alone or cells with HIV-1 only served as 
background and maximal luciferase activity, respectively. Efficacy was calculated as  
% inhibition of infection by the following formula: 
% inhibition = (Treated well-cells alone) / (HIV-1 only-cells alone) × 100 
The effective dose at 50% was calculated using GraphPad Prism software. 
 
2.2.7.3 Polarized Explant Model (PEM) 
Freshly obtained cervical tissue was incubated in a solution consisting of equal amounts 
of Penicillin-Streptomycin solution and Fungizone (Mediatech, Inc, Manassas, VA) for 10 
minutes at room temperature, then rinsed three times with RPMI media prior to use. Defined 
pieces of tissue were clamped mechanically between two neoflon cell chambers. The receptor 
chamber was filled with RPMI/10% serum/1% Penicillin-Streptomycin solution. One fourth of a 
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DPV film was weighed and dissolved in 400 μL of RPMI, and this solution was added on top of 
the tissue in the donor chamber. The tissue was then incubated with this RPMI-film preparation 
for 1 h. After incubation, the film solution was removed from the epithelial surface of the tissue, 
and the surface was rinsed several times with RAFT medium to remove any residual film. A total 
of 400 μL consisting of RAFT medium, virus inoculum, and C14-PEG 4000 (tissue integrity 
tracer) was added to the donor chamber, and the tissue was incubated for 4h to allow HIV 
infection/transmission to occur. The virus used was the dual-tropic HIV-1 89.6. After 4h, 
aliquots of both donor and receptor chamber medium were taken and reserved for further 
analysis (scintillation spectrometry, qRT-PCR of HIV-1 RNA, infectivity). 
 
2.2.7.4 Cervical Explant Model 
In this model both toxicity and anti-HIV-1 activity were assessed and set up as previously 
described [36, 53]. Briefly, explants were placed with the luminal side up in a transwell. The 
edges around the explants were sealed with Matrigel™. The explants were maintained with the 
luminal surface at the air-liquid interface. The lamina propria was immersed in medium. The 
explants were set-up in duplicate for each treatment. For toxicity testing, DPV or placebo films 
were dissolved in 2 mL of culture medium and 100 µL were applied to the apical side of the 
explants for 18 hours. The next day, explants were washed and viability was evaluated using the 
MTT assay and histology. For anti-HIV activity, 100 µL of dissolved DPV or placebo film were 
mixed with 5×10
5
 tissue culture 50% infectious dose (TCID50) of HIV-1BaL and added to the 
apical side of the explants. Eighteen hours after application the explants were washed and fresh 
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medium was applied to the basolateral compartment. Every 3 to 4 days over a 3 week period, 
supernatant was collected and stored at -80°C for HIV-1 p24 analysis and fresh medium was 
added back. Stored supernatants were tested for HIV-1 replication using an HIV-1 p24gag ELISA. 
End of study explants were fixed in 10% buffered and processed by routine paraffin embedding 
for histology to determine product efficacy by immunohistochemical (IHC) analysis for HIV-1 
p24 antigen. For toxicity evaluation, slides were stained with hematoxylin and eosin. De-
paraffinized, rehydrated sections were digested in 0.1 mg/mL Proteinase K for 15 min, washed, 
and incubated at room temperature for 1 hour with anti-p24 (dilution 1:6). Visualization was 
achieved with the DAKO Corp.’s LSAB-2 kit with the universal alkaline phosphatase system. 
Sections were counterstained in Mayer’s hematoxylin. Negative controls were tissue sections 
from each explant incubated with normal mouse ascitic fluid. 
 
2.3 Results 
2.3.1 Development and Evaluation of DPV Vaginal Film 
2.3.1.1 Film Formulation  
DPV was formulated in a polyvinyl alcohol (PVA) based vaginal film (Figure 2.1). PVA 
is used in vaginal film formulations as demonstrated by recent patent of vaginal films [137]. It is 
the main polymer in the VCF marketed film [142]. PVA constituted 38.3% (w/w) of the film. 
Other excipients in the formulation included 19.1% hydroxypropyl methyl cellulose (HPMC), 
25.5% polyethylene glycol (PEG) 8000, 7.9% glycerin and 7.9% propylene glycol.  
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In order to study the impact of drug loading on film properties two loading doses of DPV 
were evaluated: 0.5 and 1.25 mg DPV per 1”x2” film unit. These dosing levels were chosen 
based on the concentration of DPV in the vaginal gel formulation evaluated in clinical trials [71-
74]. 
 
 
 
Figure 2.1 Picture of a 2”x1” DPV vaginal film 
 
2.3.1.2 Dapivirine-Excipient Compatibility Study  
Once a film formulation prototype was selected a compatibility study of DPV with the 
excipients used in the film formulation was performed. DPV was mixed with the excipient 
mixture (propylene glycol, PVA, HPMC4000, and PEG8000) and stored at different conditions 
as described in the methods. Drug content analysis results showed that no drug loss. Stability of 
DPV in the excipient mixture was an indication of its compatibility with the excipient (Figure 
2.2). 
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Figure 2.2 DPV compatibility profile with the excipients used in the film formulation. DPV stability in the 
excipients mixture was indicative of its compatibility with the excipients 
 
2.3.1.3 Physical and Chemical Characterization 
Dapivirine films were soft, flexible and semi-transparent. A visual evaluation by 
scanning electron microscope (SEM) showed a uniform film surface which is an indication that, 
after drying, the residual water content was sufficient to maintain the polymer hydration. The 
SEM also confirmed suitable drug dispersion in the film’s polymeric network as no signs of drug 
aggregation or precipitation were observed (Figure 2.3). 
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Figure 2.3 SEM picture of 1.25 mg DPV film 
 
The thickness of the films was set to 70 μm thick which was suitable to achieve the 
required doses. Visual disintegration studies showed the quick dissolving nature of the films (< 
10 minutes). Table 2.1 shows DPV film characteristics with both dosing levels 0.5 mg and 1.25 
mg. Dosing level was found not to alter film properties. DPV loading in the film was based on 
the dosing levels of DPV in a vaginal gel that were evaluated clinically and shown to be safe and 
well tolerated [71, 74]. In DPV gel clinical trials, participants used 2.5 mL of gel products with 
increased DPV concentrations up to 0.05%. Hence, given the volume of gel administered the 
total maximum mass delivered was 1.25 mg DPV per dose. 
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Table 2.1 DPV film physical and chemical characteristics. All values presented as mean ± SD 
 
Parameter 1.25 mg DPV Film 0.5 mg DPV Film 
Weight (mg) 91.23 ± 4.93 (n = 6) 94.7 ± 10.01 (n =14) 
Thickness (mm) 0.073 ± 0.005 (n = 6) 0.063 ± 0.007  (n = 14) 
Disintegration (min) 6.33 ± 0.577 (n = 3) 4.33 ± 0.58 (n = 3) 
Water content % (w/w) 1.38 ± 0.17 (n = 3) 2.4 ± 0.19 (n = 3) 
Tensile strength (N/cm
2
) 538.24 ± 57.17 (n = 3) 777.59 ± 19.99 (n = 3) 
Drug Content % (w/w) 1.4 ± 0.03 (n = 42) 0.546 ± 0.016 (n = 5) 
 
Additionally, DPV film (1.25 mg/film) dissolution was evaluated in a class IV USP 
dissolution apparatus. Results showed that greater than 50% of the loaded DPV was released 
from the film within 10 minutes (Figure 2.4). These dissolution results confirm the quick 
dissolving property of the film. From an in vivo application stand point, it is hypothesized that 
the rapid release of DPV from the film will enhance the concentration of DPV at the tissue 
surface and thus drive diffusion of DPV into the target tissue. 
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Figure 2.4  1.25 mg DPV film dissolution. Rapid DPV release from the film was observed with >50% loaded 
drug released in less than 10 minutes. Data presented as mean±SD (n=3) 
 
2.3.1.4 In Vitro Assessment of DPV Film anti-HIV Activity 
DPV film (1.25 mg/film) was tested for anti-HIV activity in the TZM-bl assay. The EC50 
obtained for DPV in this assay was of 38.7 nM (Figure 2.5). The placebo film had minimal anti-
HIV activity which returned to baseline activity after a 1:100 dilution. This activity observed in 
the placebo film is more than likely due to the presence of the polymer excipients.  
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Furthermore, DPV film (0.5 mg/film) was tested for its ability to inhibit HIV-RT and 
cell-based HIV-1 replication in vitro. Inhibition of cell-based HIV-1 replication by DPV film 
(0.5 mg/film) is over 200-fold more potent than inhibition of RT activity (Figure 2.6). This 
observation is probably due to the hydrophobic nature of DPV. 
 
 
 
Figure 2.5 Placebo and DPV containing film anti-HIV activity in vitro in TZM-bl cell line 
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Figure 2.6 DPV film activity in vitro in cell-based HIV replication assay and in vitro RT activity assay. DPV 
showed inhibition of both HIV-1 replication and RT activity 
 
2.3.1.5 Compatibility with Lactobacillus 
Lactobacillus is a main component of the vaginal microflora. By maintaining the vaginal 
acidic pH and producing hydrogen peroxide it represents a defense mechanism against foreign 
pathogens including HIV-1 [143]. Therefore it is important to ensure that DPV film does not 
alter Lactobacillus or its function.  
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The compatibility of DPV film with Lactobacillus was assessed using the Standard 
Microbicide Safety Test (SMST). Results showed that DPV film did not induce any deteriorating 
effects on several strains of Lactobacillus as no loss of bacterial viability was observed (Table 
2.2).  
 
Table 2.2  Evaluation of DPV film compatibility with Lactobacillus. Results present are the averages of all 
experiments using the organisms.  A positive value indicates there was a slight increase in the viability. These 
organisms were tested at different time intervals.  The films passed all safety tests; the standard for passing 
the test is there cannot be a loss of viability ≥ 1 log10. 
 
Lactobacillus strain tested 
Log Difference  
(T30 minute Plate Count - T0 minute Plate Count) 
L. crispatus ATCC 33197 0.245 
L. jensenii ATCC 25258 0.0587 
L. jensenii  LBP 28Ab 0.158 
 
2.3.1.6 Stability Assessment 
After obtaining a prototype DPV film with acceptable characteristics, the film stability 
was evaluated. DPV film (1.25 mg/film) was stored at 30°C / 65% RH and 40°C / 75% RH for 
stability assessment. Based on the physical and chemical assessments conducted DPV film was 
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shown to be stable for a period of 24 months at 30°C / 65% RH and for at least 6 months at the 
accelerated conditions (40°C / 75% RH). Figures 2.7 and 2.8 show DPV film drug content, and 
dissolution obtained for each condition over the stability time period.  
 
 
 
Figure 2.7 Drug content of DPV film (1.25 mg/film) over the time course of stability testing. No change in 
DPV film content was observed 
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Figure 2.8 Dissolution of DPV film (1.25 mg/film) over the time course of stability testing. No change in DPV 
% cumulative release at 60 minutes was observed 
 
In addition, the DPV film maintained anti-HIV activity over the stability period in the 
two conditions. No cellular toxicity was observed at any time point over the stability period as 
tested in the TZM-bl assay. Furthermore, compatibility with Lactobacillus was monitored 
throughout the stability assessment period.  In the Lactobacillus film compatibility testing no 
breakdown of the film into toxic products was detected over time evident by the retained 
Lactobacillus compatibility over the period of stability testing. 
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2.3.2 Dapivirine Permeability in Human Excised Cervical Tissue 
The permeability of DPV into human excised cervical tissue was studied for both film 
formulated and unformulated DPV in a Franz cell model.  Calculated permeability parameters 
are shown in (Table 2.3). Both drug substance and film formulated DPV were able to permeate 
through the epithelium of excised human cervical tissue under the experimental conditions 
described. There was no significant difference observed between permeability coefficients 
obtained for formulated or unformulated DPV. 
 
Table 2.3 Calculated permeability parameters of DPV drug substance. Apparent permeability values 
Papp (cm/sec) for DPV drug substance and 1.25 mg DPV film. For each tissue sample, permeability testing 
was done in triplicate. Values presented as mean ± SD 
 
 1.25 mg Dapivirine film Dapivirine drug substance 
Tissue # Mean SD Mean SD 
1 1.66E-06 6.22E-07 3.66E-06 9.76E-07 
2 2.19E-06 2.81E-07 2.1E-06 1.78E-06 
3 1.15E-06 2.53E-07 3.04E-06 8.29E-07 
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2.3.3 Ex Vivo Assessment of Anti-HIV Activity 
To further confirm the bioactivity of DPV film and ensure that the film formulation did not 
lead to loss of anti-HIV activity, the bioactivity of DPV film was tested in two ex vivo models: 
an excised human cervical tissue explant model and polarized explant model (PEM). For the 
explant model tissues were treated with 100 µl of film containing 1.25 mg DPV film dissolved in 
2 ml of medium, 100 µl of placebo film dissolved in 2 ml of medium, or left untreated (control).  
Overall, both DPV and placebo film showed bioactivity with a reduction in HIV-1 p24 levels 
(Figure 2.9-A). However, all of the explants exposed to the DPV film were protected as 
compared to 6 of 8 explants protected by the placebo film. These were confirmed by IHC 
staining for HIV-1 p24 in tissues (Figure 2.9-B). In the PEM model, a piece of cervical tissue is 
clamped between two chambers mechanically. DPV film was able to block HIV-1 transmission. 
The number of HIV-1 copies as measured by qRT-PCR in the receptor compartment was below 
detection limits indicating blocking of HIV-1 transmission in the explant tissue (Table 2.4). 
 
Table 2.4 Effects of 1.25 mg DPV film on HIV-1 transmission in the polarized explant model (PEM) 
 
PEM Sample 
HIV donor 
(copies/ml) 
HIV receptor 
(copies/ml) 
HIV explants culture 
(copies/ml) 
No Treatment 2 x 10
8 
9.2 x 10
2
 1.19 x 10
5 
1.25 mg DPV Film 2 x 10
8
 Below Detection Below Detection 
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Figure 2.9  Bioactivity of 1.25 mg DPV film when tested in the excised human cervical tissue explant challenge 
model. P24 staining (in red) is the hallmark for infection. (A) P24 levels over 21 days (B) Representative 
histology pictures of tissues after 21 day of infection studies 
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2.4 Discussion and Conclusion 
The rational design of a mixture of excipients and active drug agent constitutes a 
pharmaceutical formulation. Film formulations are composed mainly of a base polymer platform 
and a plasticizer to provide flexibility to the film. Other excipients that could be used include a 
humectant to enhance soft texture, and a disintegrant to provide rapid film disintegration once in 
contact with fluids [115]. Fundamentally, the primary excipient in a film formulation is the film 
forming polymer(s). Various polymers have been used in vaginal film formulations such as 
polyvinyl alcohol (PVA) and cellulose derivatives. PVA is the polymer base which is used in 
several currently marketed vaginal film products. For this reason PVA was used as the main film 
forming polymer in the DPV film formulation. The use of another polymer was required in order 
to increase the viscosity of the polymer melt during the manufacturing process. As discussed 
later in this section higher viscosity was required to provide a uniform dispersion of DPV in the 
film solution. HPMC was used as a co-polymer. The mixture of PVA/HPMC provided the 
viscosity necessary for DPV dispersion and produced a smooth and flexible film. Sorbitol, 
propylene glycol, glycerin and combinations of these were evaluated as plasticizers for the film 
formulation. It was found that use of glycerin enhanced film flexibility, mechanical properties 
and also enhanced film softness. Given the hydrophilic nature of the polymeric composition 
(PVA/HPMC) and the hydrophobic nature of DPV, the drug was incorporated as a dispersion in 
the film product. Propylene glycol was used to facilitate the dispersion of DPV into the 
polymeric film. In addition to its role as a dispersing agent, propylene glycol served as a 
secondary plasticizer in the film. Rapid disintegration was targeted to ensure quick drug release 
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therefore PEG 8000 was included in the film formulation as a disintegrant. After preparing the 
film polymeric solution, solvent casting method was used to manufacture the films. Film 
manufacture involved pouring an 8” film sheet which was then cut into individual 1” x 2” film 
units. Content uniformity studies were conducted to ensure adequate distribution of drug was 
achieved both across the film sheet as well as within each individual film. 
The initial phase of solvent casting methods for film manufacture involves preparation of 
a solution (containing the drug and excipients) for casting. Hence it was important to establish 
that DPV did not have any incompatibility with the excipients of choice in the formulation while 
in the solution state where degradation is more likely to occur. A DPV excipient compatibility 
study was conducted with the excipients identified for utilization in the film formulation. DPV 
showed stability in the excipient mixture for 14 days at three different conditions (30°C, 40°C 
and 50°C). The compatibility study results assured DPV-excipient compatibility in the solution 
phase of the manufacturing process.  
As rapid film disintegration was targeted to ensure quick drug release, film disintegration 
and dissolution studies were conducted. Both disintegration and dissolution studies confirmed 
rapid drug release from the film formulation. The film disintegration rate as observed visually 
was less than 10 minutes. Dissolution studies showed that >50% of DPV film load is released in 
less than 10 minutes. However, it should be noted that due to the hydrophobic nature of DPV it 
was necessary to include cremophor (a nonionic surfactant) in the dissolution medium to 
maintain sink conditions throughout the dissolution experiment. As a solid dosage form, residual 
water content is important to determine in order to ensure film structural stability over time. The 
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amount of residual water in the film should be kept at levels required to maintain film flexibility 
without compromising the stability of the film. The developed DPV film had water content at 
levels of lower than 5% of film weight. After establishing acceptable film characteristics the 
stability of the film was assessed for 24 months at 30°C/65%RH and 6 months at 40°C/75%RH. 
The data confirmed that the film is stable in terms of physical, chemical and biological activity. 
As the film formulation and manufacture process includes mixing and heating, it was 
important to ensure that the shear and heat stress did not alter the anti-HIV activity of DPV. The 
anti-HIV activity of DPV films was tested in vitro in a HIV-RT assay, cell-based HIV-1 
replication assay and TZM-bl assay. In all models used, DPV formulated in the film showed 
potent anti-HIV activity. Inhibition of cell-based HIV-1 replication was over 200-fold more 
potent than inhibition of RT activity. This observation is likely due to the hydrophobic nature of 
DPV. Film dissolution leads to precipitation and substantial loss of bioactivity in pure aqueous 
media such as that used in the RT assay. However, cells provide a hydrophobic environment in 
the context of the cell membrane which can aid in sequestration of bioactive drug thereby 
leading to substantially more potent inhibition in cell-based replication assays. It should be noted 
that the 1.25 mg DPV film anti-HIV activity was not tested in HIV-RT and cell-based HIV-1 
replication assays. However, as stated in the results the 0.5 mg DPV film showed inhibition of 
HIV-1 in both assays. The 1.25 mg DPV film showed potent activity in the TZM-bl model. 
Therefore it is to be expected that the 1.25 mg DPV film would show potent inhibition of HIV-1 
in the HIV-RT and cell based HIV replication assays. The TZM-bl assay also confirmed that 
DPV films maintained potent anti-HIV activity.  
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Dapivirine works by interrupting the viral cycle at the replication step, thus it is desirable 
that DPV enters the tissue to reach the target cells which lie in the sub-epithelial layers. The 
stratified multilayer vaginal epithelium may represent a barrier for DPV permeation. For this 
reason, the permeability of DPV in both the formulated and unformulated state was evaluated 
using excised cervical tissue in a Franz-cell model to establish the permeability profile for DPV. 
No significant differences were found between the apparent permeability coefficients obtained 
for unformulated DPV as compared to those obtained for film formulated DPV. This data 
suggests that quick disintegration allows for the rapid release of DPV from the film resulting in 
permeability profiles similar to those for unformulated drug. These studies are important in that 
they establish the ability of DPV, formulated into a polymeric film, to permeate into the target 
tissue to be available for inactivation of HIV-1 viral replication. It should be noted that this data 
also suggests that DPV delivered from a film may lead to systemic absorption. That was 
observed in clinical studies with DPV vaginal ring and gel. The extent of the systemic absorption 
of DPV delivered from the film as opposed to the other dosage forms warrants evaluation. 
Although permeability studies showed that DPV was able to permeate target tissues, it is 
important to establish that this results in adequate anti-HIV activity. Ex vivo tissue models are 
widely used to understand HIV-1 transmission and evaluate anti-HIV activity of drug candidates 
[144]. For this reason, the anti-HIV activity of DPV films was studied in two ex vivo tissue 
models using human cervical explant tissue. The first is the polarized explant model which has 
been thoroughly described in the literature [36, 53].  This model uses a transwell system in which 
the tissue is sealed using matrigel establishing the polarization between the apical and basolateral 
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compartments. DPV film was shown to prevent HIV-1 infection in the tissue and that 
observation was confirmed with IHC staining for HIV-1 P24 in tissue. Additionally, developed 
and validated a polarized explant model (PEM) that can be used to study HIV-1 infection of 
cervical tissue as well as the anti-HIV activity of microbicide product candidates. In this model 
the tissue is sandwiched and mechanically sealed between a donor and receptor compartments. 
The mechanical seal provides a more thorough barrier, thus tissue permeation is more 
specifically confined to the exposed area. DPV film was shown to exhibit inhibition of HIV-1 
infection in this model as well.  
It is important that a topical microbicide product not to be harmful to the natural vaginal 
environment. It should not exert any toxic or harmful effects on the natural defenses of the local 
environment including the microflora, specifically lactobacillus as explained in section 2.3.1.5. 
DPV film compatibility with lactobacillus was evaluated. No loss of bacterial viability or 
formation of toxic products was observed. Additionally, no cellular toxicity of the film has been 
detected in the TZM-bl cell model. These studies provide evidence of safety of the film product. 
The choice of a dosage form for topical microbicides is dictated by several factors such 
as chemical characteristics of the drug candidate and user acceptability and compliance. For 
topical vaginal microbicides, hydrogels have been the main dosage form being used as they have 
a history of use in female products and an established user acceptability profile. However, 
hydrogels are usually associated with drawbacks that could suppress topical microbicide usage 
and hinder the deployment of topical microbicides because of reduced user acceptability. Thus 
alternative dosage forms are required. One dosage form option for vaginal delivery of drug 
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substances is a polymeric film. Films are easy to use, require no applicator, cause no messiness 
or leakage due to the small dose volume, and are inexpensive to manufacture. Given that 
microbicide products are specifically being targeted for undeveloped countries such as sub-
Saharan Africa where the HIV-1 epidemic is the worst, the economic feasibility of a product is 
critical to its effectiveness. More importantly, for the delivery of DPV to the tissue as a necessity 
for its function, polymeric films offer a suitable delivery system for DPV. It is anticipated that 
the rapid release and small volume of the film would create in vivo a high concentration gradient 
of DPV in the vaginal lumen which would drive DPV permeation into the mucosal tissue. 
We presented in this chapter, the feasibility of formulating a hydrophobic anti-HIV drug 
(dapivirine) into a water soluble polymeric film. DPV was successfully formulated as a vaginal 
film which provides rapid drug release, lacks toxicity to the innate microflora lactobacilli and 
maintains stability and bioactivity for 24 months. The film capacity to provide protection from 
HIV-1 infection was established in in vitro and ex vivo evaluations. This film product was 
available for studies towards understanding the role of drug release on tissue accumulation 
comparing single entity and combination film products. Particularly, the film developed in this 
chapter was used to elucidate mechanisms of DPV accumulation and distribution in human ecto-
cervical tissue (chapter 4). Given the high potency of DPV combined with advantages of the film 
dosage form, it will be valuable to evaluate this promising drug/delivery system in the clinic.  
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3. DEVELOPMENT AND EVALUATION OF DAPIVIRINE/TENOFOVIR 
COMBINATION VAGINAL FILM 
 
3.1 Introduction 
The search for an effective topical microbicide for prevention of HIV-1 sexual 
transmission is well underway. Research on strategies and approaches to enhance the efficacy of 
topical microbicides is warranted. In pursuit of that, researchers have turned to antiretroviral 
(ARV) combinations as an answer. The great degree of success associated with highly 
antiretroviral active therapy (HAART) in reducing HIV infection progression and mortality rate 
[146-148] has inspired research in the area of topical microbicides to include combination 
products. In addition to improved efficacy, benefits of combination microbicides include: 
increased barrier to infection, fewer chances of viral resistance, and possible reduction in the 
effective dose of each drug which could theoretically reduce the potential for toxicity [77]. A 
number of published scientific reports evaluated and demonstrated the benefits of different 
combinations of anti-HIV drug candidates for use in topical microbicides. Examples and details 
of those reports are discussed in chapter 1. 
Tenofovir (TFV) and dapivirine (DPV) are the two most advanced ARVs in topical 
microbicide clinical trials [43, 149]. DPV and TFV both are reverse transcriptase inhibitors but 
have different mechanisms of action. TFV is a nucleotide analog (NtRTI) whereas DPV is a tight 
binding non-nucleoside molecule (NNRTI) [47]. During transcription of viral DNA, when taken 
up, TFV is unable of forming the ester bond with the next nucleotide/nucleoside and thus 
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terminates the reverse transcription process. Whereas DPV binds to hydrophobic pocket on the 
viral reverse transcriptase enzyme preventing conformational changes required for enzymatic 
activity resulting in abrogation of the replication process. In combination TFV and DPV have 
been shown to exert additive effects against wild type HIV-1 and synergistic effects against 
NNRTI resistant HIV-1 [89]. As the two most studied and leading ARVs in topical microbicide 
clinical trials, combined with the impressive profile of their anti-HIV activity and the benefit of 
their combination, the assessment of the development of a TFV and DPV combination as a 
topical microbicide product is warranted. 
The mechanism of action of TFV and DPV demands that both be present in the target 
tissue. Drug delivery systems used for TFV and DPV alone or in combination must be able to 
deliver the drugs to the tissue. Polymeric vaginal films present a promising drug delivery system 
for the combination of TFV and DPV. The low volume of films coupled with a designed rapid 
drug release profile allow for high concentration gradient formation which is the force 
underlying drug permeation into the tissue. Additionally, films have advantages such as accurate 
dosing and portability [5, 105, 109]. Acceptability studies with vaginal films showed that women 
preferred films over other vaginal dosage forms [110-114]. Vaginal films have been 
implemented as a dosage form for a variety of drugs [117-119, 121, 124-126, 150]. Studies in 
chapter 2 describe a vaginal film containing DPV which was developed and shown to be 
effective in blocking HIV-1 infection in both in vitro and ex vivo studies. 
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The studies in this chapter were aimed toward the development of a vaginal film 
containing the combination of TFV and DPV. Formulation development, characterization and 
product stability testing are described for the combination product. 
 
3.2 Methods 
3.2.1 Drug-Drug Compatibility  
 The compatibility of TFV and DPV was evaluated in the solid and liquid state. For 
evaluations of compatibility in the solid state, 1.25 mg DPV and 40 mg TFV were mixed in a 
glass vial. Vials were then stored for 12 weeks at three conditions: 25°C, 40°C and 65°C. For 
evaluations of compatibility in the liquid state, a bulk solution containing TFV and DPV 
(TFV/DPV ratio of 32:1) was prepared using 50% acetonitrile. The bulk solution was then 
dispensed into glass vials which were stored for 12 weeks at the same conditions used for solid 
state samples.  
The concentration of each drug in the samples was monitored over time to assess 
compatibility. Solid state samples were dissolved in 50% acetonitrile and then analyzed using 
ultra-high performance liquid chromatography (UHPLC) whereas liquid state samples were 
analyzed by UHPLC without any processing. The UHPLC method for TFV determination 
utilized a reversed phase column (Acquity BEH C18 1.7 µm, 2.1×50 mm) with an isocratic 
mobile phase system composed of 10 mM dibasic potassium phosphate KH2PO4 and 2 mM t-
Butylammonium bisulfate (tBAHS), (pH 5.7) : Methanol (90:10). TFV is detected by UV 
spectrometer at 210 nm. The UHPLC method for DPV determination utilized a reversed phase 
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column (Acquity BEH C18 1.7 µm, 2.1×50 mm) with a mobile phase system composed of 
0.08% triflouro acetic acid (TFA) in water and 0.05% TFA in acetonitrile. A gradient method 
was used for drug elution where % of mobile phase (B) changed from 10 – 80 – 10 over 15 
minutes run time. DPV is detected by UV spectrometer at 290 nm.  
 
3.2.2 Solid Phase Solubility 
To investigate the ability of polymers to inhibit TFV crystal formation a solid phase 
solubility study was conducted. Different polymer/drug ratios were tested by mixing TFV with 
varied polymer amounts. The polymer/drug ratio studied were 2:1, 4:1 and 6:1.  A 1% (w/v) 
TFV solution in water was prepared by dissolving 0.05 g in 5 mL water (pH>4.5 using sodium 
hydroxide). Various polymers were added to the drug solution to achieve the specified range of 
polymer/drug ratio. Polymers screened were: sodium carboxy methyl cellulose (Na CMC), 
hydroxypropyl methyl cellulose (HPMC), hydroxyl ethyl cellulose (HEC), polyvinyl alcohol 
(PVA), and polyvinyl pyrrolidone (PVP). The amounts of the polymer added were 0.1, 0.2 and 
0.3 g. Once solutions were made, they were spread onto a glass slide and allowed to dry 
overnight at room temperature leaving a film layer on the glass slide. The film layer was then 
examined with light microscopy for visual detection of crystal growth. 
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3.2.3 Film Formulation  
The combination film formulation was composed of hydroxypropyl methyl cellulose 
(HPMC), hydroxyethyl cellulose (HEC), carboxymethyl cellulose sodium (Na CMC) and 
glycerin. Solvent casting methods were used for film manufacture. Briefly, an aqueous film 
solution containing the excipients and both drugs (TFV and DPV) was prepared. The solution 
was cast onto a polyester substrate attached to the hot surface of an automatic film applicator 
(Elcometer® 4340) using a doctor blade. The thickness of the blade was set to 115 µm. The film 
sheet was allowed to dry for 15 minutes at 70°C before it was removed from the substrate. Once 
film sheets were obtained they were cut using a die press into 2” x 2” individual units. 
 
3.2.4 Physical and Chemical Characterization 
Film weight, thickness and appearance were recorded. Tensile strength as a measure of 
film mechanical strength was assessed using a texture analyzer (TA-XT.Plus) connected to a data 
acquisition and analysis software. Puncture strength was calculated using the following equation: 
Puncture strength = Force (g) / Cross sectional area of the film (cm
2
). Residual water content of 
the films was measured using Karl-Fisher apparatus (Metrohm, 758 KFD Titrino).  
Drug content of the film was determined by means of ultra-high performance liquid 
chromatography (UHPLC). The film unit was dissolved in 40 mL 50% acetonitrile solution. 
After vortexing for 10 min, the solution was analyzed using UHPLC for determination of DPV 
content. An aliquot of the solution was diluted 20 times with 5% acetonitrile and analyzed using 
UHPLC for TFV content. The UHLPC methods used are described in the section 3.2.1.  
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Dissolution of the combination film was evaluated using class IV USP apparatus 
(SOTAX CP7) connected to a fraction collector. A 100 mL of 1% cremephor in water was used 
as the dissolution medium. The flow rate was set to 16 mL/min and the temperature was 37°C. 
Samples were collected at predetermined time points over 60 min run time. TFV and DPV 
content in the samples was determined by UHPLC methods described in the section 3.2.1.  
 
3.2.5 Anti-HIV Activity 
 Anti HIV activity was studies using a TZM-bl cell based model as described in chapter 1 
(section 2.2.7.2). 
 
3.2.6 Compatibility with Lactobacillus 
Compatibility with Lactobacillus was evaluated as per methods described in chapter 1 
(section 2.2.5). 
 
3.2.7 Stability Assessment 
The stability of the TFV/DPV film was assessed for 12 months at 25°C / 60% RH and 6 
months at 40°C / 75% RH. Testing of the film was conducted at 1, 2, 3, 6 and 12 months. At 
each time point weight, thickness, appearance, puncture strength, water content, and drug content 
were tested.  In addition, disintegration, film dissolution, Lactobacillus compatibility and in vitro 
anti-HIV activity were tested. 
66 
 
3.3 Results 
3.3.1 Tenofovir – Dapivirine Compatibility  
 The chemical compatibility of TFV and DPV was evaluated in solid and liquid states to 
ensure that the combination of these drugs can be formulated in one dosage form. The study was 
conducted at room temperature and stressed conditions in terms of temperature and humidity. 
Stability of the drugs as an indicator of compatibility was assessed by monitoring of drug content 
of both drugs over 12 weeks. As data showed, there was no significant loss of TFV (Figure 3.1) 
or DPV (Figure 3.2) observed in any sample in either solid or liquid states when exposed to the 
conditions tested. Results showed the amount of TFV and DPV to remain stable over time.  
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Figure 3.1 TFV stability in solid and liquid mix samples. Stability was ensured by comparing the % TFV 
recovered to the original TFV amount added to the sample 
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Figure 3.2 DPV stability in solid and liquid mix samples. Stability was ensured by comparing the % DPV 
recovered to the original DPV amount added to the sample 
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3.3.2 TFV/DPV Film Formulation Development 
The target loading dose for each drug candidate was: 1.25 and 40 mg per film unit 
(2”x2”) for DPV and TFV respectively. Target loading dose levels were based on the current 
dosing levels used clinically in the respective vaginal gel product for each drug [55, 58, 73, 74]. 
However at the 40 mg level, TFV was shown to exhibit crystallization in the film over time. It 
was found that 20 mg TFV could be formulated into a film without crystallization. To address 
the crystallization issue, film forming polymer in the formulation was chosen based on 
evaluation of the polymers ability to prevent TFV crystallization. Polymer choice also 
considered the film desired appearance and physical characteristics (such as peelability, 
flexibility, and brittleness).  
To identify the appropriate polymer(s) choice for prevention of TFV crystallization a 
solid phase solubility study was conducted. Six polymer types at varying concentrations were 
mixed with TFV in solution. Different polymer/drug ratios were tested to study the impact of 
increasing polymer concentration on the inhibition of TFV crystallization. Light microscopy was 
used to monitor crystallization. The results of the study are shown in table 3.1. Na CMC was 
shown to inhibit TFV crystallization at all concentrations tested. PVA was able to inhibit TFV 
crystallization when used at higher concentration. Other polymers tested showed inhibition only 
at the highest concentration tested with the exception of PVP-K30 which resulted in 
crystallization at all concentrations tested. Figure 3.3 provides example images from the 
microscopic evaluations performed in the solid phase solubility study.  
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Table 3.1 A solid phase solubility study of TFV in several potential film forming polymers was conducted to 
determine the optimal polymer for use in TFV film formulation 
 
Polymer Polymer/Drug Ratio TFV 
Na CMC 
(Sodium carboxy methyl cellulose) 
2 No crystal 
4 No crystal 
6 No crystal 
HPMC 
(hydroxypropyl methyl cellulose) 
2 Crystal 
4 Crystal 
6 No crystal 
HEC 
(hydroxyl ethyl cellulose) 
2 Crystal 
4 Crystal 
6 No crystal 
PVA 
(polyvinyl alcohol) 
2 Crystal 
4 No crystal 
6 No crystal 
PVP-K90 
(polyvinyl pyrrolidone) 
2 Crystal 
4 Crystal 
6 No crystal 
PVP-K30 
(polyvinyl pyrrolidone) 
2 Crystal 
4 Crystal 
6 Crystal 
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Figure 3.3 Example of microscopic results from the solid phase solubility study. A polymer/drug ratio of 2 
(HPMC/TFV) did not prevent crystal growth (A) whereas a ratio of 6 (HPMC/TFV) showed no crystal 
growth in the film layer (B) 
 
The data generated from the solid phase solubility study was used to direct polymer 
excipient choice for the TFV/DPV film formulation. Different combinations of the polymers 
selected were used to make multiple film formulations. The prototype films were exposed to 
stress conditions (temperature of 50°C) for 15 days to monitor TFV crystallization. A 
formulation containing the combination of 5% HPMC, 2% Na CMC, and 5% HEC with 2% 
glycerin as a plasticizer showed no TFV crystallization in the film for 15 days at 50°C.  
 
A B 
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3.3.3 Physical – Chemical Characterization 
The developed combination film was characterized in terms of chemical, physical and 
biological attributes. Table 3.2 shows the physical and chemical characteristics obtained for the 
optimized TFV/DPV film formulation. 
 
 Table 3.2 Physical and chemical characteristics of TFV/DPV film 
 
Parameter TFV/DPV Film 
Weight (mg) 312.43 ± 6.89 (n=12) 
Thickness (um) 90 ± 10 (n=12) 
% Water Content (w/w) 9.14 ± 0.64 (n=3) 
Puncture Strength (g/cm
2
) 27.09 ± 2.22 (n=3) 
% Drug Content (w/w) TFV 7.18 ± 0.24 (n=3) 
DPV 0.396 ± 0.01 (n=3) 
 
Analysis by means of UHPLC showed that the film’s drug content was accurate when 
compared to the theoretical target dose for each drug. TFV loading accuracy in the film was 
111.15 % in whereas DPV loading accuracy was 98.40 % of the theoretical target dose.  
The dissolution of TFV/DPV film was assessed using a USP class 4 flow through system. 
1% cremophor in water was used as the dissolution medium to provide sink conditions for both 
TFV and DPV. Results showed that the release of TFV and DPV from the film was rapid. Figure 
3.4 shows the release profile of DPV and TFV from the combination film. The majority of the 
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loaded TFV was released within 30 min with 96.01 ± 1.08 % released whereas only 51.32 ± 7.19 
% DPV was released within the same time frame. TFV solubility in the medium was measured to 
be ~7.5 mg/mL whereas DPV solubility in the medium is ~40 μg/mL. This difference in 
solubility explains the more rapid TFV release from the film compared to the release of DPV 
from the same film. 
 
 
 
Figure 3.4 TFV/DPV film dissolution as tested in class IV USP apparatus 
 
3.3.4 Anti-HIV Activity 
TFV/DPV film anti-HIV activity was assessed in vitro using a TZM-bl cell based model. 
The film showed potent anti-HIV activity. HIV-1 infection inhibition was evaluated for the 
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0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60
%
 R
e
le
a
s
e
 
Time (min) 
Tenofovir
Dapivirine
74 
 
film was found to be 550 nM whereas the single entity TFV film had an EC50 value of 6170 nM. 
The EC50 for DPV was about 30 nM in both the combination and DPV film (Figure 3.5). There 
was no loss in cell viability as a result of cells exposure to the combination film.  
 
3.3.5 Compatibility with Lactobacillus 
The compatibility of the combination film with Lactobacillus was assessed using the 
Standard Microbicide Safety Test (SMST). The film did not exhibit toxic effect on several 
strains of Lactobacillus as no loss of bacteria viability was observed (Table 3.3).  
 
Table 3.3 Compatibility of TFV/DPV film with Lactobacillus. After 30 min incubation of the bacteria with the 
films no loss of growth was observed indicating no harmful impact of the film on the bacteria 
 
Lactobacillus strain tested 
Log Difference  
(T30 minute Plate Count - T0 minute Plate Count) 
L. crispatus ATCC 33197 0.125 
L. jensenii ATCC 25258 -0.085 
L. jensenii LBP 28Ab -0.150 
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Figure 3.5 Anti-HIV activity of TFV and DPV in single entity and combination films as tested in TZM-bl cell 
based model 
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3.3.6 Stability Assessment 
The stability of the developed TFV/DPV film was evaluated for 6 months at 40°C/75% 
RH and 12 months at 25°C/60% RH. In addition to weight, thickness, water content, and 
puncture strength, film dissolution, drug content, compatibility with Lactobacillus and anti-HIV 
activity were evaluated. Figure 3.6 shows the drug content results for DPV and TFV during the 
duration of the stability study. There was no difference in TFV and DPV content in the film over 
the stability period tested confirming that both TFV and DPV were stable in the film. In vitro 
ant-HIV activity testing did confirm as well that the film maintained its anti-HIV activity over 6 
months as was indicated by their EC50 values (Table 3.4). Results showed that all other 
parameters tested for the film were stable throughout the stability study. 
 
Table 3.4 Anti-HIV activity of TFV and DPV in the combination film over 6 months stability monitoring 
 
 Tenofovir EC50 (µM) Dapivirine EC50 (nM) 
Time Zero 0.55 29.18 
3 months 25°C/60%RH 1.41 76.42 
40°C/75%RH 1.26 68.19 
6 months 25°C/60%RH 0.27 14.53 
40°C/75%RH 0.35 18.89 
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Figure 3.6 Drug content results of TFV/DPV film over 12 months of stability monitoring 
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3.4 Discussion and Conclusion 
The development of a topical microbicide containing a combination of ARVs entails an 
added layer of complexity in order to incorporate two active agents into one dosage form. For a 
combination product to be successfully formulated it is important first to assess the chemical 
compatibility of the drug candidates with each other. Such information is important to establish 
that the two active agents can be formulated into the same dosage form. Therefore to formulate 
TFV and DPV into a polymeric film the compatibility of both drug candidates with each other 
was evaluated. The stability of the two drug candidates in both the solid and liquid state was 
monitored at different conditions by measuring the DPV and TFV content in the samples over 12 
weeks. Data showed that TFV and DPV are chemically compatible with each other as their drug 
content in solid and liquid state samples was stable at all conditions tested. No degradation 
products were identified from the chromatograms at any time point evaluated. 
A typical vaginal film formulation is composed of film forming polymer(s), plasticizer, 
and API [115]. Polymer choice is critical to film attributes and properties. Most importantly, 
excipients should be chosen which maintain the physical and/or chemical stability of the active 
agent. The formulation of DPV and TFV combination into a single film product faced challenges 
given the opposing solubility of these two drug candidates. Because of the hydrophilic nature of 
TFV, it was solubilized in the hydrophilic polymers of the film whereas the hydrophobic drug 
DPV remained dispersed in the solid state. However, after solvent casting the amount of water 
(solvent) in the film decreases drastically thus potentially causing over-saturation of TFV 
solubility in the film matrix that could cause TFV to precipitate out. TFV precipitation could lead 
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to drug crystallization in the film. For that reason, the polymer selection process was based 
primarily on the ability of each individual polymer to prevent TFV crystallization. Several 
polymers used in film formulation showed ability to prevent TFV crystallization at different 
polymer concentrations. Sodium CMC showed complete inhibition of TFV crystallization at all 
concentrations tested. Other polymers prevented TFV crystal growth at the higher concentrations 
included HEC, HPMC and PVA. The ability of a polymer to inhibit API crystallization is 
dependent on the magnitude of its interaction with the active agent [151, 152]. TFV is a weak 
acid and its solubility in water is >150 mg/mL when pH is greater than 4.5. At that pH level 
sodium CMC works as a weak base which allows for acid-base bond formation between the 
polymer and TFV. Hydrogen bonding is another possible mechanism by which TFV can interact 
with the polymers screened. CMC, HEC, HPMC and PVA all are capable of hydrogen bonding. 
The interaction between TFV and the polymers can lead to the formation of a boundary layer in 
which the polymer accumulates on the surface of TFV preventing aggregation and 
crystallization.  
The developed TFV/DPV film was characterized in terms of its physical, chemical and 
biological properties. The characterization of the film included: weight, thickness, residual water 
content and puncture strength. The residual water content of the film is an important parameter. 
The residual water maintains polymers hydration and network formation thus consequently plays 
a role in the films physical appearance and attributes. Therefore in the TFV/DPV film developed 
the residual water content was kept at levels required for polymer hydration. The residual water 
content of both films was less than 10% of film weight which maintained good film flexibility. 
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Films with residual water content of more than 10% failed to stabilize TFV and prevent crystal 
growth. The mechanical property of puncture strength was measured for the TFV/DPV film. The 
puncture strength exhibited by both films was deemed appropriate for films to handle stress. The 
film was flexible and able to withstand folding induced stress without breaking.  
Dissolution testing of TFV/DPV film showed that greater than 50% of the TFV and DPV 
loading levels were released within 30 minutes. In molar values, by 30 min, ~ 60 µM TFV and ~ 
1.9 µM DPV was released from the film. The released amounts of both drugs are at levels which 
are much higher than the reported in vitro IC50 for TFV and DPV (~2 μM for TFV and less than 
10 nM for DPV) [64, 153]. 
The anti-HIV activity of TFV and DPV was evaluated in a TZM-bl cell based model after 
film formulation to ensure that the formulation or manufacturing did not lead to loss of activity. 
The film showed potent anti-HIV activity indicating that TFV and DPV activity was not altered 
due to formulation. It is noteworthy to point out that TFV exhibited more potent anti-HIV 
activity in the combination film as compared to the single entity film illustrated by the decrease 
in EC50 value for TFV in the combination film. It is likely that this observation is due to the 
presence of DPV which has significantly greater anti-HIV activity than TFV. A topical 
microbicide product should not be toxic to the vaginal environment. In the TZM-bl cell model, 
the TFV/DPV film did not alter cell viability indicating no toxicity towards the cells. 
Additionally, a compatibility assessment of the film with Lactobacillus was conducted. The 
results showed no sign of any toxic effects of the film on the Lactobacillus. The stability of the 
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TFV/DPV film was evaluated for 12 months. Data collected confirmed that the film is stable as 
no significant changes in its physical, chemical or anti-HIV activity were observed.  
The work presented in this chapter showed that a vaginal film containing a combination 
of TFV/DPV was successfully developed. The thorough in vitro testing showed that the film has 
acceptable characteristics and exerts potent anti-HIV activity with no sign of toxic impact on the 
major components of the normal vaginal flora. This developed film will be used in studies 
conducted chapter 4 towards understanding the impact of co-delivery of TFV and DPV on tissue 
accumulation and distribution.  
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4. THE IMPACT OF DAPIVIRINE AND TENOFOVIR CO-DELIVERY ON THEIR 
TISSUE ACCUMMULATION AND DISTRIBUTION IN HUMAN ECTO-
CERVICAL TISSUE 
 
4.1 Introduction 
As reverse transcriptase inhibitors, the mechanism of action of DPV and TFV demands 
their presence in the mucosal tissue or cells. From a drug delivery stand point, the efficacy of a 
topical microbicide containing DPV and/or TFV depends in part on the ability to deliver the 
drugs into the mucosal tissue. The relationship of cellular or tissue concentration to product 
efficacy was illustrated in the pharmacokinetic studies with TFV vaginal gel discussed in section 
1.4.3. The studies conducted in chapter 3 resulted in the development of a polymeric film 
containing a combination of both DPV and TFV. As a solid dosage form films have a small 
volume which minimizes the dilution effect with vaginal administration in vivo. Theoretically, 
that would create a higher concentration of DPV and TFV upon release from the film on the 
mucosal tissue surface which would drive tissue permeation by diffusion of the film load of TFV 
and DPV. However, an understanding of the impact of the co-delivery of both drugs on their 
tissue accumulation is needed. 
Multiple pre-clinical and clinical studies established that DPV permeates and 
accumulates in various cells and tissues. DPV was shown to permeate and accumulate in a HEC-
1A cell line [128]. After 1 hour incubation period, 56% of loaded DPV was present inside the 
cells. Similar results were obtained by das Neves et al. where free DPV was shown to permeate 
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and accumulate in a CaSki cell monolayer and pig vaginal mucosa after a 4 hour exposure period 
[154]. Nanoparticle formulations were found to alter the permeability and retention of DPV in 
the two models. Several clinical pharmacokinetic studies with DPV microbicide gel and ring 
showed that DPV accumulates locally in the female lower genital mucosa [71, 73-76]. In two 
phase I clinical studies, DPV vaginal rings (200 and 25 mg DPV) applied for 7 days delivered 
DPV to the lower genital tract mucosal tissue while exhibiting low systemic absorption [75]. The 
mean concentration of DPV in vaginal and cervical tissue biopsies was found to be higher for the 
25 mg DPV ring (1.5-3.5 µg/g) than for the 200 mg DPV ring (0.3-0.7 µg/g). In another phase I 
clinical study, DPV vaginal gels (0.001, 0.005 and 0.02%) applied for 10 consecutive days 
showed demonstrated low systemic absorption and good distribution in the lower genital tract as 
analysis of all biopsies taken from the vagina and cervix showed presence of DPV [73].  
Evidence also exists for permeation of TFV into mucosal tissue. Animal studies and 
human clinical trials have demonstrated that TFV delivered in a gel dosage form permeated and 
accumulated in tissues of the lower genital tract. A pharmacokinetic study conducted in rabbits 
showed that a once daily application of a 1% TFV gel led to high TFV accumulation in vaginal 
fluid and tissue [155]. In macaques, vaginal application of TFV gel resulted in rapid TFV 
distribution in cervix and vagina [156]. In animals exposed to a 1% TFV gel, drug concentration 
in tissue remained detectable for 24 hours after dosing. This macaque data was confirmed in 
human clinical trials where data showed that a single dose and multiple doses of a 1% TFV 
vaginal gel exposure resulted in high genital tract concentrations for at least 24 hours post-dose 
with minimal systemic absorption [157]. Tenofovir diphosphate (TFV-DP), the active 
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metabolite, was detectable in approximately 40% of all tissue samples collected in the study. In a 
separate clinical study, vaginal dosing of 1% TFV gel (40 mg per dose) was shown to be superior 
to oral dosing of TFV (300 mg per tablet) in terms of accumulation of TFV in lower genital tract 
tissue [158]. TFV-DP in vaginal tissue was quantifiable in ≥90% of women following vaginal 
dosing. Only 19% of vaginal tissue biopsies obtained from women following oral dosing were 
shown to have quantifiable TFV-DP. Additionally, TFV-DP in vaginal tissue was ≥130 fold 
higher with vaginal dosing compared to oral dosing. 
In each of the studies described above either TFV or DPV was evaluated as a single 
entity product. To advance a film containing DPV and TFV to the clinic it is important to 
establish the ability of the film to deliver both agents to the target tissue and understand the 
impact of their co-delivery on their tissue accumulation. Therefore, the aim of the studies 
conducted in chapter 4 was to evaluate DPV and TFV tissue accumulation and distribution in 
human ecto-cervical tissue after tissue exposure to a vaginal film containing DPV and TFV.  
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4.2 Methods 
4.2.1 Tissue Exposure Studies 
Human ecto-cervical tissue was obtained from University of Pittsburgh Health Sciences 
Tissue Bank under IRB protocol PRO09110431. Tissue samples were from healthy volunteers 
undergoing routine hysterectomy for non-cervical reasons. 
4.2.1.1 Tenofovir/Dapivirine Vaginal Film 
In these studies flow through diffusion cells were used. Excised human ecto-cervical 
tissue was placed in between donor and receptor compartments. Before tissue placement excess 
stromal tissue was removed using a Thomas Stadie Riggs tissue slicer. The test article introduced 
into the donor compartment was a single 6mm biopsy punch of TFV/DPV (20/1.25 mg) film, 
DPV (1.25 mg) film or TFV (20 mg) film with 450 µL vaginal fluid stimulant (VFS). The 
receptor medium used was Dulbecco's Modified Eagle Medium (DMEM) at a flow rate of 50 
µL/min. Excised human ecto-cervical tissue was exposed to each film for 6 hours and the cells 
were water jacketed to maintain a temperature of 37°C. 3 mL receptor sample was collected 
throughout the experiment every hour for 6 hours. After the exposure period, the tissue was cut 
in half. One half was processed for histological evaluation and epithelial thickness measurement 
whereas the second half was used for the determination of TFV and DPV concentration by 
LC/MS/MS. The tissues used for determination of DPV and TFV content were embedded into 
blocks using Optimal Cutting Temperature (O.C.T) compound and sectioned by cryostat. Fifteen 
(20 μm) sections were cut followed by cutting of (200 μm) sections for the remainder of the 
tissue. 
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4.2.1.2 Dapivirine Vaginal Film 
In these studies Franz cells were used where excised human ecto-cervical tissue was 
placed between the donor and receptor compartments. Before tissue placement excess stromal 
tissue was removed using a Thomas Stadie Riggs tissue slicer. The receptor medium used was 
vaginal fluid simulant (VFS) at (pH=4.2). Four different product application scenarios were 
modeled by altering the test article introduced into the donor compartment as follows:  
Test article 1- Single 6mm biopsy punch of DPV (1.25 mg) film + 450 µL VFS 
Test article 2- Double 6mm biopsy punches of DPV (1.25 mg) film + 450 µL VFS 
Test article 3- 100 µL aliquot of DPV (1.25 mg) film dissolved in 0.5 mL VFS 
Test article 4- 100 µL aliquot of DPV (1.25 mg) film dissolved in 1.5 mL VFS 
The tissue was exposed to each test article for 6 hours. Franz cells were water jacketed to 
maintain a temperature of 37°C throughout the exposure period. 200 μL sample from the 
receptor was collected every hour for 6 hours. After the exposure period, the tissue was cut in 
half and one half was processed for histological evaluation and epithelial thickness measurement 
whereas the second half was used for the determination of DPV concentration by LC/MS/MS. 
The tissues used for determination of DPV content were embedded into blocks using an O.C.T 
compound and sectioned by cryostat into 100 μm sections. In a separate set of experiments the 
sectioning protocol was modified to elucidate DPV epithelial distribution. The protocol was 
modified such that the tissues were sectioned into 15 (20 μm) sections followed by (200 μm) 
sections for the remainder of the tissue. 
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4.2.1.3 C14 – Dapivirine 
In these studies excised human ecto-cervical tissue was placed between the donor and 
receptor compartments of a neoflon two compartment diffusion cell. Prior to tissue placement the 
excess stromal tissue was removed using a Thomas Stadie Riggs tissue slicer. The receptor 
medium used was VFS at (pH=4.2). Three different product application scenarios were modeled 
by altering the test article introduced into the donor compartment as follows:  
Test article 1- 5 µL of C
14
-DPV solution (250 µCi/mL) + 445 µL VFS 
Test article 2- 10 µL of C
14
-DPV solution (250 µCi/mL) + 440 µL VFS 
Test article 3- 15 µL of C
14
-DPV solution (250 µCi/mL) + 435 µL VFS 
The purpose of testing three different test articles was to assess the impact of increased 
concentration of the radio labeled drug in the donor compartment on the distribution of the drug 
in the tissue. The tissue was exposed to each loading scenario for 6 hours. The experimental 
setup was maintained at a temperature of 37°C. After the exposure period, the tissue was cut in 
half and one half was processed for histological evaluation and epithelial thickness measurement 
whereas the second half was impeded in O.C.T blocks and cut by a cryostat into sections. 
Autoradiography was conducted on tissue sections. 
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4.2.2 Determination of Drug Concentration in Human Ecto-Cervical Tissue Sections  
4.2.2.1 Dapivirine 
Tissue samples (sections) from the exposure study were homogenized. Tissue 
homogenates were then transferred to extraction tubes. A liquid extraction with a mixture of 
methanol, acetonitrile and MTBE (methyl-tert-butyl ether) was used to extract DPV. After 
drying under nitrogen, final samples were reconstituted in 500 μL of the injection solvent (6:2:2) 
(acetonitrile:water:100 mM ammonium formate buffer). Samples were injected onto an ultra-
high performance liquid chromatography (UHPLC) connected to a triple quad mass spectrometer 
(with electric spray ionization source) for analysis. The column used was a Phenomenex 
Hyperclone 3u BSD C8 150x4.6 mm.  A gradient method was used for separation which 
consisted of two mobile phases (A: 12.5 mM NH4FA Buffer in 60% acetonitrile and B: 25 mM 
NH4FA Buffer in 80 % acetonitrile). Mobile phase gradient was setup so that the percentage of 
acetonitrile increased from 60% to 80% over 1.5 minutes, held at 80% for 2 minutes then 
equilibrated back to 60% for the rest of the run. A 40 µL injection volume was used and the run 
time was 6 min with a flow rate of 1 mL/min. A positive SRM scan was used to monitor: 330.2 
 158 for DPV and 334  145.1 for d4-DPV (internal standard). The standard curve prepared 
over the range of 0.2-50 ng/mL was determined to be linear. The concentration of DPV in 
unknown samples was determined by the plot of concentration vs area (ratio of DPV/ d
4
-DPV) 
with the equation: y = ax + b where y is the area and x is the concentration (ng/mL). 
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4.2.2.2 Tenofovir 
Tissue samples (sections) from the exposure study were homogenized. Tissue 
homogenates were then transferred to extraction tubes. TFV was extracted from the homogenate 
using a methanol liquid extraction. Final samples were reconstituted in 100 μL of a 0.1% formic 
acid solution. Samples were injected onto a UHPLC/MS/MS (with electric spray ionization 
source) for quantification of TFV. The column used was an Agilent ZORBAX XDB-C18 5 µm, 
4.6x50 mm.  A gradient method was used for separation which consisted of two mobile phases 
(A: 0.1% formic acid in water and B: 0.1% formic acid in methanol). Mobile phase gradient was 
setup so that the percentage of methanol increased from 5% to 50% over 2 minutes, held at 50% 
for 0.5 minute then equilibrated back to 5% for the rest of the run. A 10 µL injection volume was 
used and the run time was 5 min with a flow rate of 0.5 mL/min. A positive SRM scan was used 
to monitor: 288  176.1 for TFV and 293  181.1 for C15-TFV (internal standard). The 
standard curve prepared over the range of 5-250 ng/mL was determined to be linear. The 
concentration of TFV in unknown samples was determined by the plot of concentration vs area 
(ratio of TFV/ C
15
-TFV) with the equation: y = ax + b where y is the area and x is the 
concentration (ng/mL). 
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4.2.3 Autoradiography 
In a dark room, slides of tissue sections were taken from -20°C and allowed to come to 
room temperature. Once at room temperature the slides were processed using KODAK NTB 
autoradiography emulsion which was pre-heated to 45°C in a water bath. The slides were then air 
dried for 15 minutes. Once dry, slides were stored at 4°C for 20 hours in a black box. After the 
incubation period, the slides were developed and fixed per manufacturer instructions using 
KODAK developer D-19 and KODAK fixer.  
 
4.2.4 In Vitro Release 
A diffusion cell system connected to an automated fraction collector was used for these 
studies. A cellulose membrane (Spectra/Por 1 MWCO 6000-8000 Da, Diameter 33 mm) was 
placed between the donor and receptor compartments. A single 6mm biopsy punch of TFV/DPV, 
TFV or DPV film was placed into 450 μL VFS in the donor compartment. The receptor 
compartment medium used was 1% cremophor in water. The run time was 6 hours and 37°C was 
maintained by a water jacket. 500 μL from the receptor was sampled every hour for 6 hours. 
Sample analysis of DPV and TFV was conducted using a UHPLC. The methods for TFV and 
DPV content analysis were previously described in section 3.2.1. 
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4.2.5 Statistical Analysis 
For comparison of drug tissue concentrations and in vitro release data, a Student T-test 
was used to compare the difference in mean values between single entity and combination film 
exposure groups (p < 0.05 was considered significant).  One-Way ANOVA was used to compare 
difference in mean values of drug accumulation across the epithelium (p < 0.05 was considered 
significant).  
 
4.3 Results 
4.3.1 Drug Accumulation in Human Ecto-Cervical Tissue after Exposure to DPV/TFV 
Vaginal Film 
Human ecto-cervical tissue was exposed to a TFV/DPV, DPV or TFV vaginal film ex 
vivo. Flow-through diffusion cells were utilized for these studies in order to closely simulate in 
vivo application of the product. Analysis of drug content in tissues was conducted using 
UHPLC/MS/MS. Results showed that, after 6 hours, TFV and DPV were present in the tissue 
whether the exposure was using a single entity or combination film. (Table 4.1). However, when 
comparing the tissue concentrations of DPV between the single entity and combination film 
groups, the data showed that tissue exposure to the combination film resulted in significantly 
higher DPV accumulation (p < 0.05). The amount of DPV in the tissue exposed to the 
combination film was approximately twice as much as of that found in the tissue exposed to the 
single entity film (0.5 and 1.1 µg DPV for single entity and combination film groups 
respectively).  
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Table 4.1  Concentration and amount of DPV in human ecto-cervical tissue after 6 hour exposure  
to DPV film or DPV/TFV film.  
* p<0.05 (Student t-Test) 
 
 DPV Film DPV/TFV Film 
Concentration in Tissue (µg/g)* 14.21 ± 4.13 (n=6) 31.03 ± 12.63 (n=7) 
Amount in Tissue (µg)* 0.50 ± 0.22 (n=6) 1.10 ± 0.28 (n=7) 
 
Since the epithelium represents a rate limiting barrier to diffusion, its thickness plays a 
role in drug tissue accumulation. Further analysis revealed that there is no difference in DPV 
levels in the epithelium as a result of the exposure to either the single entity or the combination 
films (Figure 4.1). Thus, it was concluded that the observed significant difference in DPV whole 
tissue amounts could be correlated with DPV stromal localization. 
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Figure 4.1 DPV amount throughout the epithelium of human ecto-cervical mucsoa 
 
With regard to TFV, no significant difference in TFV whole tissue amounts was observed 
between the single entity and the combination film groups after the 6 hours exposure period 
(Table 4.2). Evaluation of TFV amounts localized in the epithelium only showed no significant 
difference in TFV epithelial amounts between the two film groups (Figure 4.2). 
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Table 4.2 Concentration and amount of TFV in human ecto-cervical tissue after 6 hour exposure  
to TFV film or TFV/DPV film 
 
 TFV Film TFV/DPV Film 
Concentration in Tissue (µg/g) 33.88 ± 8.67 (n=7) 34.92 ± 14.98 (n=6) 
Amount in Tissue (µg) 1.46 ± 0.53 (n=7) 1.45 ± 0.75 (n=6) 
 
 
 
 
Figure 4.2 TFV amount throughout the epithelium of human ecto-cervical mucsoa 
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4.3.2 Drug Accumulation in Human Ecto-Cervical Tissue after Exposure to DPV Vaginal 
Film 
In order to elucidate why DPV accumulated higher when co-delivered with TFV it was 
important to first understand the mechanism of DPV tissue permeation when delivered from a 
film. For that purpose human ecto-cervical tissue exposure studies to a DPV vaginal film using a 
simulated in vivo situation were conducted. Vaginal fluid simulant was utilized in these studies 
as the medium in the donor and receptor compartments. Different scenarios associated with 
varied DPV concentrations in the donor were investigated as described in the methods section 
4.2.1.2. The various scenarios, chosen for evaluation, simulate potential film behavior following 
in vivo administration.  
Results showed that DPV could be found throughout the ecto-cervical tissue (Figure 4.3). 
This indicates that the film was able to release drug allowing for its permeation into the tissue. 
DPV tissue permeation was found to be dependent on the concentration of DPV in the donor. 
The highest exposure concentration resulted in the greatest DPV tissue concentration  
(98.68 µg/g) (Table 4.3). This suggests that DPV tissue permeation is primarily due to passive 
diffusion. By examining the amount of DPV per tissue section from the epithelium to the stroma 
it was noticeable that DPV amounts were highest at a level of roughly 200 – 500 µm. This level 
can be correlated with the location of the basal layer of the epithelium and the beginning of the 
stroma. Considering that major HIV-1 targets (represented by CD4 T-cells) exist in the sub-
epithelium, DPV accumulation at the basal layer of the epithelium is likely to be desirable.  
 
97 
 
Table 4.3 Tissue concentration of DPV (µg/g) in human ecto-cervical tissue after different exposures to DPV 
vaginal film 
 
Scenario DPV Tissue Concentration (µg/g) 
Single 6mm punch 47.45 ± 25.40 
Double 6mm punch 62.54 ± 24.08 
Aliquot of film/1.5 mL 97.56 ± 6.67 
Aliquot of film/0.5 mL 98.68 ± 44.22 
 
 
 
Figure 4.3 Amount of DPV (ng) per 100 µm section throughout human ecto-cervical tissue after 6 hours 
exposure to DPV vaginal film 
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When looking at DPV amount in the epithelium only, no drug gradient was identified 
(Figure 4.4). There was no significant difference in DPV amounts throughout the epithelium. 
 
 
 
Figure 4.4 Dapivirine amount (ng) throughout the epithelium across human ecto-cervical mucosa 
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permeation and accumulation after exposure to the DPV vaginal film. However, the results of the 
permeability study in chapter 2 showed that film formulation did not have an impact on DPV 
tissue permeability owing to the quick release of DPV from the film. Additionally, these results 
suggest that the film formulation excipients did not cause a deterioration of the epithelium as a 
barrier. On the other hand, the findings of the tissue exposure studies in this section showed that 
the quick release characteristic of the film allowed for DPV permeation into the tissue as indicted 
in the presence of the drug across the tissue. Taken together, the findings from the two studies 
showed that the film formulation of DPV does not change its tissue permeation while being able 
to deliver DPV to the tissue. 
 
4.3.3 Human Ecto-Cervical Tissue Exposure to C14-DPV  
In order to visualize the distribution of DPV in human ecto-cervical tissue, C
14
 labeled 
DPV was used. Tissue exposure studies were conducted in a similar experimental setup as that 
used for DPV film exposure studies. The donor compartment contained three different 
concentrations (2.78, 5.56 and 8.33 µCi/mL) of C
14
-DPV in VFS. After a 6 hour exposure 
period, the tissues were sectioned and autoradiography was performed. As shown in figure 4.5 
the radio labeled DPV diffused through the epithelium. With increasing donor C
14
-DPV 
concentration accumulation of C
14
-DPV (represented by a band of black dots) tissue localization 
became more evident. Visual data obtained from autoradiography confirms concentration 
dependent localization of DPV in the tissue observed in the findings of the previously described 
tissue exposure studies with the DPV film. 
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Figure 4.5 C
14
-DPV distribution throughout human ecto-cervical tissue after 6 hour exposure period to 
different concentrations of the radioactive material. (A) negative control (B) 2.78 (C) 5.56 (D) 8.33 µCi/mL 
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4.3.4 DPV/TFV Combination Film In Vitro Release 
Since DPV tissue permeation was found to be driven by passive diffusion, it can be 
hypothesized that the difference in DPV tissue concentration, after tissue exposure to single 
entity or combination film products, can be attributed to a faster DPV release from the 
combination film. To test this hypothesis in vitro drug release was tested in a similar setup to the 
tissue exposure studies. In vitro drug release experiments used the same donor as the tissue 
exposure studies. However, the receptor utilized in the in vitro drug release studies was 1% 
surfactant in water. The use of this receptor medium was necessary from a technical stand point 
to create the sink condition effect produced by the tissue in the exposure studies. The results 
showed that DPV was released faster from the combination film than the single entity film. By 4 
hours the % released of DPV from the combination film was 6.15±1.42 compared to 4.42±0.88 
from the single entity film. This observed difference was statistically significant (p < 0.05). At 
the end of the experiment (6 hours) the % released of DPV was 9.44±2.17 and 6.33±0.83 for the 
combination and single entity film respectively which was also a significant difference (p < 
0.05). Figure 4.6 shows DPV release plotted as % released over time. The release of TFV from 
the single entity and the combination film was not different. At the end of the experiment (6 
hours) the % released of TFV was 39.73±2.19 and 41.09±1.26 for the combination and single 
entity film respectively. The plot of % release of TFV over time is shown in figure 4.7. 
The obtained values of % drug released after 6 hours was low considering the quick 
release profile of the film as described in chapter 3. It is important to emphasize that the USP 
system used in in vitro release studies in chapter 3 has large volume of medium in continuous 
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circulation, compared to the diffusion cell system used in studies in this section. Whereas in the 
cell diffusion system, the donor contains only 450 μL medium which makes the process of DPV 
solubilization slow and does not provide enough volume to solubilize the entire TFV amount 
present in the 6mm film punch. 
 
 
 
Figure 4.6 DPV release from the DPV and DPV/TFV films 
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Figure 4.7 TFV release from the DPV and TFV/DPV films 
 
4.4 Discussion and Conclusion 
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The studies conducted in this chapter were aimed to understand the impact of co-delivery 
of DPV and TFV from a vaginal film on their tissue accumulation and distribution. The dosing 
levels of DPV and TFV in the film are in line with levels being evaluated in clinical trials. The 
experimental setup chosen used flow through diffusion cells to simulate blood flow in vivo and 
maintained sink condition. Single entity and combination films of DPV and TFV were 
compared. Film formulation excipients were identical so any impact of formulation on the 
permeability of both drugs into the tissue was similar. The results confirmed the ability of the 
films to deliver DPV and TFV to the tissue whether formulated individually or in combination. 
In theory, a solid dosage, polymeric film minimizes dilution effect of the active agents 
concentration released from the film. This creates a higher concentration of the active agent on 
the tissue surface which drives drug tissue permeation. Further mathematical interpretation of the 
obtained data which scales the data from the amount of DPV in the film punch used in the 
exposure study to the total film DPV content shows that following 6 hours of tissue exposure to a 
whole film unit, approximately 152 or 334 nM DPV would be delivered from single entity or 
combination films respectively. These values represent levels which are much higher than the 
reported EC50 for DPV (1 nM in CEM T-cells) [65]. Similar calculations for TFV show that by 6 
hours the tissue exposed to an entire film unit would contain roughly 0.45 µM TFV delivered 
from either the single entity or combination film. This value is within the reported TFV IC50 
range of 0.04-8.5 µM [159]. 
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With regard to the impact of the combination on DPV and TFV tissue accumulation, the 
data showed that there was a significant difference of DPV concentration between tissues 
exposed to the single entity film as compared to the combination film. Further analysis of DPV 
amounts in the epithelium showed no difference between the two film groups which indicates 
that the observed difference in whole tissue amounts between groups is primarily due to 
differences in DPV accumulation in the stroma. Theoretically, since most HIV-1 target cells are 
located in the stroma, the increased DPV stromal accumulation may lead to better protection of 
HIV-1 target cells located there. This finding further supports use of the TFV/DPV combination 
film as a topical microbicide. On the other hand increased DPV stromal accumulation may lead 
to higher systemic absorption of DPV as increased drug amounts would be in closer proximity to 
blood circulation. Systemic absorption could lead to or increase chances for selection of drug 
resistant HIV-1 strains. Therefore the potential consequences of increased DPV stromal 
accumulation on efficacy and systemic absorption should be further evaluated. With regard to 
TFV, the co-delivery of TFV and DPV in a film formulation did not have any influence on TFV 
tissue accumulation. TFV tissue concentrations were similar between the single entity and 
combination film exposed tissues. The epithelial TFV amounts were also similar between the 
two film groups suggesting no advantage from a TFV tissue accumulation stand point for the 
combination product. 
To understand why DPV accumulation was higher after tissue exposure to the 
combination film, it was first necessary to understand how DPV permeates into ecto-cervical 
tissue after exposure to DPV film. From an application stand point, vaginal films could be 
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inserted folded or unfolded and later disintegrate or form a gel mass depending on the 
formulation excipients and amounts of fluid present at the time of application. The loading in the 
donor compartment in the exposure studies with DPV film was designed so that it simulated 
these potential scenarios. Results showed that DPV accumulation in the tissue was concentration 
dependent which is consistent with passive diffusion. As a hydrophobic molecule, it is expected 
that DPV permeates into the tissue through transcellular pathway passive diffusion. The 
sectioning of the tissue allowed for clearer elucidation of where DPV accumulates in the tissue. 
It was found that DPV generally accumulated equally throughout the tissue from the epithelium 
to the stroma. However, DPV highest amounts were found to be around 200 - 500 µm deep into 
the tissue. The thickness of the epithelium was variable among tissues used in the study and 
ranged between 100 – 200 µm. By comparing thickness of the epithelium with DPV 
accumulation pattern one can see that DPV formed a reservoir at the basal layer of the epithelium 
and through the upper part of the stroma. For further examination of DPV amount in the 
epithelium, the exposed tissues were sectioned into 20 µm sections for the first 300 µm of the 
tissue which goes beyond the epithelial thickness in most cases. The data showed that there is no 
difference in DPV amounts throughout the epithelium. A slight trend towards increased DPV 
amounts at the basal layer can be seen which is consistent with the observation of DPV reservoir 
formation as described previously.  
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Visualization of DPV accumulation in human ecto-cervical tissue was made possible 
using C
14
-DPV. Tissue exposure studies were conducted using unformulated C
14
-DPV. Three 
donor C
14
-DPV concentration levels were tested to show the impact of increased concentration. 
The data confirmed radio labeled DPV accumulation throughout the tissue with highest 
accumulation at the basal epithelial cells or upper stroma. 
Since DPV enters the tissue mainly by passive diffusion, it is logical to assume that the 
increased DPV tissue concentration after exposure to the combination film is a result of a higher 
DPV concentration in the donor. A higher concentration in the donor would mean that the release 
of DPV from the combination film is faster than its release from the single entity film. This 
assumption was tested by assessing the in vitro release of DPV and TFV from the single entity 
and combination films in a diffusion cell system similar to that used in the exposure studies. The 
data showed that no difference in TFV release existed between the single entity and combination 
film. Whereas DPV release from the combination film was faster than its release from the single 
entity film. The increased DPV release from the combination film can be attributed to several 
factors. Since TFV is a hydrophilic compound with weak acidic properties, it is expected that 
TFV would be released quickly from the film upon contact with fluids (VFS used the 
experiment). This was demonstrated experimentally through in vitro release studies  where it can 
be observed that by two hours the % TFV released was approximately 10 times higher than that 
of DPV (Figure 4.6 and 4.7). Considering that TFV is a week acid, its rapid release leads to a 
decrease in the pH of the medium. DPV chemical structure contains two amine groups which can 
be protonated in an acidic pH environment leading to an increased solubility of DPV in the 
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medium. Increased DPV solubility can enhance DPV release from the film matrix. Another 
potential contributing factor to increased DPV release from the combination film is the high 
loading level of TFV in the film.  Since TFV is a major component of the overall film network, 
its rapid release results in a decreased barrier for DPV diffusion from the polymeric network. 
Either of these scenarios (increased solubility in the medium and/or increased diffusivity through 
the film polymeric network) would lead to more rapid release of DPV from the combination 
film.  Consequently yielding a higher DPV concentration on the apical surface of the tissue 
would lead to increased DPV tissue diffusion and higher tissue accumulation.  
In conclusion, TFV and DPV delivered from a vaginal polymeric film were shown to 
permeate into human ecto-cervical tissue after ex vivo exposure to a film containing either drug 
or both in combination. Co-delivery of TFV and DPV had no impact on TFV tissue 
accumulation but resulted in significant increased DPV tissue accumulation. This increased 
tissue accumulation was found to be associated with faster DPV release from the combination 
film. The mechanism by which DPV permeates through the tissue is passive diffusion. DPV was 
shown to form a reservoir at the base of the epithelium or upper stroma. It is warranted to study 
whether this observed increased in DPV tissue concentration will result in enhanced efficacy 
and/or systemic exposure. The data presented sheds light on the impact of co-delivery of ARV 
combinations from a polymeric film on tissue levels and points out to the importance of pre-
clinical studies to evaluate delivery efficiency and factors that impact it.  
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5. DISCUSSION OF MAJOR FINDINGS AND FUTURE DIRECTIONS 
 
5.1 Major Findings, Implications and Limitations 
  Although slower than a decade ago, the continued rise in new HIV infections worldwide 
poses a serious health challenge. It also points to the fact that available prevention strategies 
from educational interventions to promoting safe sexual practices have not been enough to bring 
about a significant decline in HIV infection rates. On the other hand, vaccination against HIV 
infection has not been successful and AIDS (the outcome disease of an HIV infection) is still 
incurable. Therefore, research on all three fronts to combat the HIV epidemic is warranted. 
 Since sexual transmission is the primary source of new HIV infections, prevention 
methods focused on sexual transmission are in pursuit. Topical microbicides are part of the 
broader pre-exposure prophylaxis (PrEP) products which are designed for use in a healthy HIV 
negative population. The work presented and discussed in this dissertation is focused in the area 
of topical vaginal microbicide product development. 
In its early stages topical microbicide research has produced several candidate products 
that were evaluated in clinical trials. Unfortunately, none of the products has proven successful. 
However, the introduction of HIV specific antiretrovirals (ARVs) to topical microbicide research 
led to the first success in human trials. A phase IIb clinical trial (CAPRISA004) the product 1% 
TFV gel was able to reduce HIV acquisition by 39% when administered within 12 hours before 
sexual intercourse and within 12 hours after [58]. However, this result has not been consistently 
shown and has yet to be validated in a phase III clinical trial. Meanwhile, the use of ARVs 
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combinations in topical microbicides has become a research focus toward improvement of 
product efficacy. This concept has been extrapolated from the HIV therapy field where ARV 
combination therapy has resulted in significant improvement of clinical outcomes.  
 One of the aspects related to topical microbicide product development is dosage form 
choice. Dosage form choice is a multifaceted process dictated by factors ranging from the active 
agent(s) properties to user acceptability. For some ARVs being evaluated for use in topical 
microbicides, one aspect which is particularly important is the ability of the dosage form to 
deliver the drugs into the genital mucosal tissue. With this said, given the emphasis on 
combination product development the impact of co-delivery on ARVs tissue accumulation needs 
to be considered for development of efficient and functional dosage forms given that drug tissue 
accumulation, for ARVs, can influence their ability to block HIV-1 infection. 
 The work conducted in this dissertation was based on the hypothesis that a polymeric 
film can serve as a delivery system for a combination of DPV and TFV and that the film will be 
able to deliver both agents to the tissue. However, co-delivery of DPV and TFV will lead to a 
change in their accumulation in human ecto-cervical tissue due to associated concentration 
gradient changes. The studies conducted to address the hypothesis included the development of a 
polymeric vaginal film containing DPV and TFV and the evaluation of DPV and TFV 
accumulation in human ecto-cervical tissue after exposure to the combination film. The major 
findings of the dissertation are summarized below. 
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5.1.1 Polymeric Films for Topical Delivery of Antiretrovirals (ARVs) 
 Considering that no marketed vaginal film product contains a hydrophobic molecule and 
the majority of polymers approved or have history of use in vaginal products are water soluble, it 
was needed to ensure the ability of formulating DPV in a water soluble film. Due to its 
hydrophobicity, DPV was to be dispersed in the film formulation. Thus the polymer selection 
was guided by the ability of the polymeric mix to maintain DPV in a uniformly dispersed state 
throughout the manufacturing process and in the solid film unit after solvent evaporation. A 
combination of PVA and HPMC was found to be suitable for incorporation of DPV into the film. 
The type and ratio of PVA and HPMC can be manipulated to change the viscosity of the 
polymeric film solution, disintegration and dissolution of the film. The other main excipient used 
for film formulation is the plasticizer. After screening multiple plasticizers, glycerin was chosen 
for use as a plasticizer in the film formulation based on its ability to provide the film with 
flexibility and enhance its smoothness. DPV was dispersed in propylene glycol and subsequently 
incorporated in the film formulation. In the case of the combination film, the attempt to 
incorporate TFV into the developed DPV film was unsuccessful due to the inability of the PVA-
HPMC polymeric network to inhibit TFV crystallization at the target loading dose. For that 
reason, a solid phase solubility study of TFV in several polymers was conducted to identify 
polymers capable of stabilizing TFV in the film formulation. Using the results of the solid phase 
solubility study, several polymeric compositions were made and stressed at high temperature to 
test the ability of each composition to prevent TFV crystallization in the film matrix.  
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A combination of Na CMC, HPMC and HEC was found to be successful in producing a film 
matrix which could successfully solubilize TFV. It is highly likely that the interaction of the 
polymer with TFV is the primary factor associated with inhibition of TFV crystallization. Since 
the plasticizers function in the film formulation is to maintain a loose and flexible network, too 
much network flexibility could allow for TFV molecules to move more freely which may lead to 
drug crystallization. Glycerin amount (the plasticizer of choice) in the formulation was optimized 
to balance network flexibility and drug stability.  
 A comprehensive evaluation of the films was conducted. Physical parameters (weight, 
thickness, appearance), chemical parameters (residual water content, disintegration, dissolution, 
drug content), mechanical parameters (tensile or puncture strength), toxicity and anti-HIV 
activity all were assessed. Both films exhibited acceptable characteristics. Their in vitro toxicity 
and anti-HIV activity were established in TZM-bl cell based model which is one of the most 
widely used in HIV research. This model utilizes a genetically engineered HeLa cell line that 
expresses CD4, CXCR4 and CCR5 and contains Tat-inducible Luciferase and -Gal reporter 
genes. These cells are readily infected by a wide array of HIV-1 isolates. The film formulation 
did not alter the anti-HIV potency of TFV or DPV in the TZM-bl cells. The EC50 of both drugs 
formulated was similar to their EC50 as unformulated drugs. Drug release from the films was 
rapid. In either film, more than 50% of the loading dose was released within 30 minutes into an 
aqueous medium. It is to be noted that the specification for quick release were set for testing with 
a flow through class IV USP apparatus. Film dissolution and drug release is a multistep process. 
As a solid dosage form, the steps dictating drug release from a film dosage form are 
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disintegration, deaggregation and solubilization. The slowest step in the process is the rate 
limiting step. For water soluble polymeric films, such as the ones described in this dissertation, it 
is more than likely that all three steps of drug release occur simultaneously. The drug release 
profiles of DPV film (chapter 2) and TFV/DPV film (chapter 3) show a quick initial release of 
drug followed by a reduction in the release rate. Hence this release profile is consistent with first-
order release kinetics. In either film product, once the film is in contact with the dissolution 
medium the polymers of the film hydrate which results in polymer relaxation. At the same time, 
polymer erosion occurs. The two processes of polymer relaxation and hydration are the primary 
factors which drive film disintegration and deaggregation. In addition to polymer relaxation and 
erosion, drug solubilization also occurs. The combined effect of the three processes creates, in 
the first part of drug release, a polymeric matrix with high concentration of the active agent. This 
matrix is surrounded by a boundary layer of the medium. In a class IV USP apparatus, the 
continuous flow of medium ensures low concentration of the active agent at the boundary layer – 
medium interface which, coupled with the high concentration of the active agent in the matrix – 
boundary layer interface, forms a steep concentration gradient in the boundary layer. Drug 
release is driven by the concentration gradient in the boundary layer. This concentration gradient 
is initially high which is visualized in the release profile of DPV film and TFV/DPV film 
showing rapid drug release. With the depletion of the drug from the matrix over time, the 
concentration gradient in the boundary layer decreases resulting in a reduction in drug release 
rate and solubility becomes the rate limiting step of the process. The dependence of the release 
rate on the concentration gradient can be described as a first-order release process. In the 
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TFV/DPV film the release of TFV is faster than that of DPV due to the higher TFV solubility in 
the release medium. Rapid drug release from the product is an essential attribute for topical 
microbicides intended to be used in a coitally dependent fashion. That would ensure that the drug 
reaches its target before HIV and prevent infection.  
Finally, the stability of the two film products was evaluated. Both films demonstrated 
stability physical, chemical and pharmacological stability. 24 months stability data for the DPV 
film and 12 months for the TFV/DPV film was acquired. Stability testing of the TFV/DPV film 
is ongoing and planned for 24 months.  
 Overall, the data demonstrated the feasibility of use of polymeric films as a dosage form 
for ARVs as topical microbicides. The advancement in polymer science allows for great 
versatility in film design in order to tailor it to the needs of the product and its application. As 
solid dosage forms, films offer an excellent alternative to hydrogels for topical microbicide 
development. Importantly, the developed DPV film was recently evaluated in a macaque animal 
model for safety and pharmacokinetics and is currently being evaluated for safety and 
pharmacokinetics in a phase I human clinical trial outside of the scope of this dissertation. 
  
5.1.2 Co-delivery of ARVs: Impact on Tissue Accumulation 
 Since ARVs work at the cellular level, their tissue accumulation and distribution are key 
to their bioactivity and hence success in topical microbicides. The tissue penetration and 
accumulation of ARVs in genital mucosa can be affected by the delivery system or dosage form 
chosen. Further drug tissue localization is a reflection of the delivery efficiency of the product. 
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 As hypothesized, the polymeric film successfully delivered DPV and TFV into the tissue 
when presented either in combination or individually. As demonstrated in studies with the film 
products, the release of the drugs from the dosage form was quick. Rapid release from the 
product results in increased drug concentration at the tissue surface which drives permeation of 
the drug into the tissue through diffusion processes. DPV is hydrophobic and is expected to 
permeate the tissue via transcellular pathway. In this pathway, DPV preferably partitions to the 
lipid bi-layer of the cell membrane where it gets solubilized creating a concentration gradient in 
the cell membrane driving its diffusion through the cell. TFV is hydrophilic and is expected to 
permeate the tissue primarily through the paracellular pathway. The spaces between the 
epithelial cells are aqueous and molecules soluble in water, such as TFV, can diffuse through the 
epithelium via these inter-cellular channels. 
 Another major finding from the tissue exposure studies was that co-delivery of DPV and 
TFV using the film dosage form at a loading level of 20/1.25 mg (TFV/DPV) resulted in a 
significant increase in DPV accumulation in the tissue. TFV tissue accumulation was not 
affected by co-delivery. To dissect the mechanism for increased DPV tissue accumulation, it was 
essential to understand the mechanistic pathway by which DPV accumulates in the tissue.  
Data generated show that the higher the concentration at the tissue surface, the higher the 
accumulation of DPV in the tissue. This is consistent with the passive diffusion process which 
was anticipated for DPV tissue permeation. For the combination film to cause a higher DPV 
tissue accumulation the prediction was that the combination film is releasing higher DPV 
amounts which would translate into an increased concentration of DPV at the tissue surface. To 
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evaluate that, in vitro release studies were conducted in diffusion cells similar to those used in 
the tissue exposure studies. As predicted, the release of DPV from the combination film was 
faster than that for DPV only film.  
 The third finding from these studies was that both TFV and DPV distribute evenly 
throughout the epithelium following a 6 hour exposure of the tissue to the film product. The 
distribution of the drugs across the epithelium provides a consistent barrier for protection from 
HIV infection.  
 An additional important finding from the exposure studies related to DPV tissue 
distribution. Despite the fact that DPV distributed across the tissue from the epithelium to the 
stroma it showed the highest amounts at the basal epithelial layer through the upper stroma. That 
was confirmed using radio labeled DPV and autoradiography. This drug distribution pattern 
matches the relative distribution of HIV-1 target cells in the genital mucosa. CD4 T-cells (HIV-1 
main target cells) have been found to form a cluster band directly beneath the epithelium and 
infiltrating the epithelium to some extent [31]. Based on the mechanism of action of DPV, the 
co-localization of DPV with cellular targets may be beneficial from a bioactivity stand point. 
 
5.1.3 Implications for Topical Microbicides Development  
As current research and development of topical microbicides is moving towards the use 
of HIV specific ARVs in topical microbicide products, the work presented in this dissertation 
contributes to the advancement of topical microbicides by providing the first ever ARV 
containing vaginal film for evaluation in clinical trials as topical microbicide product for HIV-1 
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sexual transmission prevention. Furthermore, considering that ARVs combinations are being 
pursued as a strategy to enhance topical microbicide products effectiveness, the developed 
combination (TFV/DPV) film product is positioned as a pipeline product for further preclinical 
and clinical assessment. This is the first combination film product containing two ARVs. Both 
the DPV and TFV/DPV film products have been tested in a comprehensive algorithm that 
evaluated their physical, chemical properties, toxicity and anti-HIV activity. The results showed 
that the products developed within the scope of this work are ready for further development and 
warrant further evaluation. 
From a dosage form perspective, the findings of this work validate polymeric films as a 
delivery platform that can be utilized in the design of topical microbicide products.  
The data showed the versatility and potential application of polymeric films for vaginal delivery 
of ARVs. The findings confirmed that films are able to deliver two chemically different active 
agents, whether formulated individually or in combination, to the target tissue. 
Combining these data with studies showing that women preferred and rated films high and 
acceptable for vaginal use, this dosage form provides a promising platform for administration of 
anti-HIV drugs. The addition of the film dosage form to the existing platforms currently being 
used for vaginal administration of microbicide drug candidates provides an additional product 
option to users.  Considering the diversity of target female populations who would use a topical 
microbicide product, greater options may lead to enhanced compliant product use which will 
positively impact product efficacy.   
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Published reports have established the benefit of the TFV/DPV combination by 
demonstrating synergistic activity against NNRTI HIV resistance strains. The findings of the 
work in this dissertation provide, to our knowledge, the first demonstration of the benefits of the 
TFV/DPV combination from a drug delivery perspective. The observed enhancement of DPV 
release from the combination film was found to be correlated with enhanced tissue 
concentrations.  From a pharmacokinetic perspective this observation is important as it has been 
shown that for ARVs, drug tissue levels are linked to product efficacy. Hence this data provides 
further rationale for development of this combination.   
 
5.1.4 Limitations 
 With regard to film product development, although the films developed within the scope 
of this dissertation showed acceptable properties, the lack of universal standard target 
specifications for vaginal films makes the development process somewhat subjective to one’s 
perspective of what is acceptable. Additionally, no clinically relevant target loading dose or 
release profile has been identified for the field or for vaginal administration of DPV or TFV. 
Thus the development process was guided by the requirements to produce a film that proves 
stable, acceptable, safe and effective in the available models for testing.  
 The tissue exposure studies provided valuable information on the accumulation and 
distribution of TFV and DPV in lower female genital mucosa. For technical reasons, the tissues 
used were all frozen and thawed at the time of experiments. This may have compromised the 
effect of transport and permeation processes. However, previously no impact of freezing and 
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thawing on the diffusion pathway of small molecules was found [160, 161]. The impact of co-
delivery of TFV and DPV was found to be dependent on drug exposure level at the tissue 
surface. However, since no target tissue concentration for effectiveness has been identified for 
TFV and DPV to date, the relevance of this finding to a marketable product with large scale 
implementation may require re-evaluation once the optimal drug loading levels are identified.  
 
5.2 Proposed Future Studies 
This research has identified several future studies which can contribute to further 
development of the TFV/DPV film as well as expand concepts developed regarding drug tissue 
accumulation. Below is a list of proposed studies which can enhance the findings from work 
conducted within this dissertation: 
 
1- The stability study of TFV/DPV film must be completed. 12 months of data has been 
collected to date, however, the study is planned for 24 months and acquiring 24 
months stability data would support advancement of this product to clinical testing. 
2- Testing the efficacy of the TFV/DPV film in an ex vivo cervical tissue explant model 
would provide further confirmation of the impact of these findings on anti-HIV 
activity. It will be important to correlate bioactivity with findings from tissue 
exposure studies to understand if increased DPV tissue accumulation is associated 
with enhanced efficacy. 
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3- The tissue exposure studies should be further expanded to include different exposure 
periods, more tissue replicates, and use of fresh tissue. All of which would further 
validate the model and the results. Different exposure periods would provide data 
essential to evaluate the kinetics of drug penetration and the impact of the co-
delivery. This information is important especially in the extent of coital use. 
Additionally, it would be informative to conduct comparative tissue exposure studies 
of DPV film and gel products in order to understand the impact of dosage form 
differences on tissue drug accumulation. 
4- It is valuable to validate the findings of the tissue exposure studies conducted ex vivo 
with in vivo data from an animal study (Macaque). These studies would be possible to 
conduct by administering the film product to macaques prior to necropsy. Whole 
reproductive tract would be collected after animal sacrifice and drug levels could be 
then analyzed in the mucosal tissue.  
5- Given that animal and human pharmacokinetic studies are being conducted with the 
developed DPV film from this dissertation, it would be feasible to develop a 
mathematical pharmacokinetic model to predict the in vivo delivery efficiency of the 
film. A recent study with the TFV vaginal gel presented an example of the 
development of a multi-compartment pharmacokinetic model to study the delivery of 
TFV from the gel and understand formulation and physiological parameters 
impacting product performance [162]. 
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Appendix I 
Dapivirine Clinical Trials (October 2013) 
 
TRIAL NAME DESCRIPTION STATUS 
IPM 001 Dapivirine ring safety (Ring-001) Completed 
IPM 008 Dapivirine ring safety (Ring-002) Completed 
IPM 018 Dapivirine ring safety & PK (Ring 002 & 003) Completed 
IPM 011 Placebo ring acceptability & safety Completed 
IPM 024 Dapivirine ring safety & PK (Ring-004) Completed 
IPM 013 Dapivirine ring safety & PK (Ring-004) Completed 
IPM 015 Dapivirine ring safety (Ring-004) Completed 
IPM 027 (The Ring Study) Dapivirine ring long-term safety & efficacy (Ring-004) Ongoing 
IPM 007 Seroconverter protocol Ongoing 
MTN-020 (ASPIRE) Dapivirine ring safety & effectiveness (Ring-004) Ongoing 
IPM 003 Dapivirine gel safety & PK (Gel-002) Completed 
IPM 004 Dapivirine gel PK (Gel-002) Completed 
IPM 005B Dapivirine gel safety (Gel-002) Completed 
IPM 012 Dapivirine gel PK & safety (Gels 4750 & 4789) Completed 
IPM 020 Dapivirine gel safety (Gels 4759 & 4789) Completed 
IPM 014A Dapivirine gel safety & acceptability (Gel 4759) Completed 
IPM 014B Dapivirine gel safety & acceptability (Gel 4789) Completed 
MTN-012 / IPM 010 Dapivirine gel male tolerance (Gel 4759) Completed 
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Appendix II 
Ongoing Topical Microbicides Clinical Trials (October 2013) 
 
TRIAL NAME PHASE POPULATION CANDIDATE(S) 
FACTS 001 III 2900 Women 1% TFV gel 
IPM 027  III 1650 Women 4-week vaginal DPV ring 
MTN 020  III 3476 Women 4-week vaginal DPV ring 
CAPRISA 008 III 700 Women 1% TFV gel 
MTN 017 II 
186 Transgender, Men who 
have sex with men (MSM) 
Daily oral TDF/FTC, Reformulated 
rectal 1% TFV gel 
MTN 005 I/II 252 Women Placebo vaginal ring 
Project Gel I 240 MSM 
1% TFV rectal gel, HEC placebo 
rectal gel 
MTN 008 I 105 Women 1% TFV gel 
CONRAD 120 I 36 Women 1% TFV vaginal ring 
CONRAD 118 I 54 Women 
1% TFV gel, Antifungal cream, 
Antimicrobial gel, Contraceptive ring 
CONRAD 117 I 48 Women 
TFV/FTC fast dissolve vaginal tablet, 
TFV-only fast dissolve vaginal tablet 
CONRAD 114 I 72 Women 
1% TFV gel, Depo-provera, Oral 
contraceptive 
NNRTI Microbicide 
Gel 
I 30 Women 
Carageenan-based placebo gel, MIV-
150/Zinc acetate vaginal gel 
IPM 026/MTN 013 I 
48 Women 
 
4-week vaginal DPV ring, 4-week 
vaginal DPV-MVC ring, 4-week 
vaginal MVC ring 
MTN 011 I 48 Men, Women 1% TFV gel 
MTN 014 I 28 Women 
Reformulated rectal 1% TFV gel, 
Reformulated vaginal 1% TFV gel 
CONRAD A10-114 I 72 Women 1% TFV gel 
Vaginal Microbicide 
Adherence 
Other 70 Women Dye Stain Assay, UV-Light, Wisebag 
Sex Workers Study Other 267 Women HEC placebo vaginal gel 
MTN 003B Other 518 Women Daily oral TDF/FTC, Oral TDF 
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